PRENATAL ALCOHOL EXPOSURE AND CHILD COGNITION: SEMI-CONTINUOUS EXPOSURES, CAUSAL INFERENCE AND EVIDENCE SYNTHESIS

Xiaoya Wang*

Department of Statistics and Actuarial Science University of Waterloo Waterloo, ON N2L 3G1, Canada x932wang@uwaterloo.ca

Yeying Zhu

Department of Statistics and Actuarial Science University of Waterloo Waterloo, ON N2L 3G1, Canada yeying.zhu@uwaterloo.ca

R. Colin Carter

Departments of Emergency Medicine and Pediatrics Columbia University New York, NY 10032, USA rcc2142@cumc.columbia.edu

Joseph L. Jacobson

Department of Psychiatry and Behavioral Neurosciences
Wayne State University
Detroit, MI 48202, USA
joseph.jacobson@wayne.edu

Richard J. Cook

Department of Statistics and Actuarial Science University of Waterloo Waterloo, ON N2L 3G1, Canada rjcook@uwaterloo.ca

Tugba Akkaya-Hocagil

Department of Biostatistics, School of Medicine Ankara University Ankara, Ankara 06230, Turkey tahocagil@ankara.edu.tr

Sandra W. Jacobson

Department of Psychiatry and Behavioral Neurosciences
Wayne State University
Detroit, MI 48202, USA
sandra.jacobson@wayne.edu

Louise M. Ryan

School of Mathematical and Physical Sciences University of Technology Sydney Sydney, NSW 2007, Australia louise.m.ryan@uts.edu.au

December 11, 2025

ABSTRACT

We address the challenge of causal inference status and the dose-response effects with a semicontinuous exposure. A two-stage approach is proposed using estimating equation for multiple outcomes with large sample properties derived for the resulting estimators. Homogeneity tests are developed to assess whether causal effects of exposure status and the dose-response effects are the same across multiple outcomes. A global homogeneity test is also developed to assess whether the effect of exposure status (exposed/not exposed) and the dose-response effect of the continuous exposure level are each equal across all outcomes. The methods of estimation and testing are rigorously evaluated in simulation studies and applied to a motivating study on the effects of prenatal alcohol exposure on childhood cognition defined by executive function (EF), academic achievement in math, and learning and memory (LM).

^{*}Use footnote for providing further information about author (webpage, alternative address)—not for acknowledging funding agencies.

1 Introduction

1.1 Background

Methodology for causal inference is essential for understanding the effects of exposures on health outcomes. Propensity scores were originally developed to facilitate estimation of causal effects of binary exposures in observational studies (Rubin, 1974; Rosenbaum and Rubin, 1983, 1984). The generalized propensity score extends this framework to continuous exposures, broadening its applicability to a wider class of problems (Hirano and Imbens, 2004; Imai and Van Dyk, 2004). However, an increasing number of causal inference problems involve semi-continuous exposures, characterised by a point mass at zero and a continuous distribution of positive values among the exposed. Akkaya-Hocagil et al. (2021) propose a two-part propensity score model in which one component represents exposure status and the other the exposure dose among those exposed. Li et al. (2023) conduct a two-stage analysis, first examining the effect of the continuous component and subsequently that of the binary exposure. Wang et al. (2025) establish a potential outcomes framework for semi-continuous exposures, derive large sample properties, and evaluate the robustness of the two-stage approach. These contributions provide a foundation for analyzing semi-continuous exposures but are restricted to a setting involving a single outcome.

Evidence from epidemiological studies suggests that prenatal alcohol exposure (PAE) affects multiple domains of cognitive function and behaviour. A recent large-scale individual-participant meta-analysis across six U.S. longitudinal cohorts estimates the effects of PAE on executive function (EF), learning and memory (LM), reading, mathematics, and behaviourial problems (Jacobson et al., 2021). The results suggest negative effects across all domains, with particularly strong effects on learning and memory. Such findings motivate the need for statistical methods capable of assessing causal effects of semi-continuous exposures on multiple correlated outcomes simultaneously. Various multivariate modelling strategies have been developed to handle correlated outcomes. Multivariate linear mixed models separate mean and correlation parameters to provide robust estimation (Sammel et al., 1999), and scaled linear mixed models standardise regression coefficients by outcome variability, enabling estimation of outcome-specific and global effects while accounting for within-subject correlation (Lin et al., 2000; Roy et al., 2003). Bayesian approaches further accommodate complex nested outcomes to enhance power and flexibility (Thurston et al., 2009). More recent doubly robust and semi-parametric frameworks extend causal inference to multiple outcomes of differing types or scales, offering inference for standardized treatment effects while controlling for multiplicity (Kennedy et al., 2019; Lupparelli and Mattei, 2020; Du et al., 2025). Nevertheless, there remains a need for methods for inference about causal effects of a semi-continuous exposure on multiple outcomes. We address this here.

We extend the two-stage causal analysis of Wang et al. (2025) to provide a robust approach to careful nuanced study of the causal effects. Synthesis of evidence across outcomes can increase power but is informative only when effects are homogeneous and synthesis yields interpretable effects. We therefore develop homogeneity tests to assess whether exposure effects are similar across outcomes and propose pooled estimation when evidence of heterogeneity is weak. Understanding the pattern of heterogeneity can help identify which domains are most affected by PAE and can guide targeted interventions.

1.2 A prenatal alcohol exposure study in Detroit

The Detroit Longitudinal Cohort Study examines prenatal alcohol exposure in children born to 480 pregnant African-American women from inner-city Detroit between 1986 and 1989 (Jacobson et al., 2002, 2004). Alcohol consumption during pregnancy is assessed through timeline follow-back interviews conducted at each prenatal visit. The average daily intake is measured in standard drinks or ounces of absolute alcohol (AA) per day. A total of 377 children completed the 7-year follow-up. Among their mothers, 16.2% report no alcohol use during pregnancy. The resulting distribution of PAE exhibits a prominent mass at zero and a long right-skewed tail among the exposed, reflecting the semi-continuous nature of the exposure; this pattern is illustrated in Figure 1. Prenatal alcohol exposure is then modelled as a semi-continuous variable, where drinking status is treated as a binary exposure and the logarithm of AA per day is used as a continuous measure among drinkers. The Detroit Longitudinal Cohort Study is therefore a large-scale prospective investigation designed to examine the impact of both drinking status and exposure dose on childhood cognition (Jacobson et al., 2004, 2002).

Children were followed up to 19 years of age with cognition measured by, among other indices, the Freedom from Distractibility Index from the Wechsler Intelligence Scale for Children, 3rd Edition (WISC-III). The study assesses three cognitive domains—executive function (EF), mathematics (Math), and learning and memory (LM) using 7, 2, and 6 tests respectively. EF tests comprehensively cover flexible thinking (switching between tasks), self-control (stopping automatic responses), holding information in mind, and planning. Two tests in Math cover accurate calculation and solving practical problems. LM tests focus on learning new material, remembering it soon and after a delay, and recognising what was learned from lists and stories. Dang et al. (2023) use a first-order confirmatory factor analysis






Figure 1: Distribution of prenatal alcohol exposure (AA/day) in the Detroit cohort





A SEM for deriving domain-level outcomes in the Detroit cohort. Rectangles denote observed test groups and ellipses denote latent variables. Single-headed arrows are factor loadings. Double-headed arrows between test boxes denote residual correlations, and self-loops on latent variables denote factor variances.

B Directed acyclic graph (DAG) for a semi-continuous exposure.

Figure 2: Overview of the problem: Panel (A) shows the SEM measurement model used to construct domain-level outcomes; panel (B) shows the causal DAG for the two-part exposure structure used in the two-stage analysis.

within a structural equation modeling framework to create one latent score for each domain; Figure 2A describes the structural relation.

A broad range of maternal, child, and environmental characteristics are included as potential confounders; these are summarized in Table 4 and briefly described below. Maternal smoking during pregnancy is measured as the average number of cigarettes smoked per day, while socioeconomic status at birth is assessed using the Hollingshead Four-Factor Index. Child's gender is recorded as a binary indicator for female, and maternal age is measured at the time of delivery. The prenatal Beck Depression Inventory (BDI) score captures depressive symptoms during pregnancy, and the HOME score at infancy reflects the quality of the cognitive and emotional environment in the home. The biological mother's Peabody Picture Vocabulary Test–Revised (PPVT-R) score is used to evaluate verbal intelligence, and marital status is recorded at the time of the child's birth. Prenatal exposures to cocaine, marijuana, and opiates are measured by

the number of days each substance was used per month during pregnancy. The number of prenatal visits is obtained from medical records, and maternal education is recorded as the total number of years of formal schooling. Parity and gravidity capture the number of previous live births and total pregnancies, respectively. Finally, gestational age at screening is measured in weeks.

2 Description of the problem

2.1 Notation and assumptions

Consider a sample of n independent individuals indexed by $i=1,\ldots,n$. Let \mathbf{Y}_i be a $J\times 1$ vector of continuous response variables where $\mathbf{Y}_i=(Y_{i1},Y_{i2},\ldots,Y_{iJ})'$. Let T_i $(T_i>0)$ represent a non-negative random variable that measures the daily volume of alcohol consumed (exposure) by individual i who is exposed and A_i be a binary indicator of exposure status where $A_i=I(T_i>0)$. Let $\mathbf{X}_{i1}=(X_{i11},\ldots,X_{i1k_1})'$ be a $k_1\times 1$ vector of confounding variables associated with the continuous variable T_i and the response vector \mathbf{Y}_i among those exposed, $\mathbf{X}_{i2}=(X_{i21},\ldots,X_{i2k_2})'$ be a $k_2\times 1$ vector of confounders associated with the binary exposure indicator A_i and \mathbf{Y}_i , and $\mathbf{X}_{i3}=(X_{i31},\ldots,X_{i3k_3})'$ be a $k_3\times 1$ vector of confounders associated with (T_i,A_i) , and the response \mathbf{Y}_i . The directed acyclic graph (DAG) in Figure 2B depicts the relationship among the variables and shows the different roles of the \mathbf{X}_i variables. Let $\mathbf{X}_i=(\mathbf{X}'_{i1},\mathbf{X}'_{i2},\mathbf{X}'_{i3})'$ be a $k\times 1$ vector comprised of three types of confounding variables with $k=k_1+k_2+k_3$. We let $\mathbf{Z}_{i1}=(\mathbf{X}'_{i1},\mathbf{X}'_{i3})'$ to represent the k_1+k_3 confounders associated with the continuous exposure T_i and the response vector \mathbf{Y}_i , and $\mathbf{Z}_{i2}=(\mathbf{X}'_{i2},\mathbf{X}'_{i3})'$ to denote the k_2+k_3 confounders associated with the binary exposure A_i and the response vector \mathbf{Y}_i . We consider a linear model for $D_i=\log T_i$ which we refer to as the dose of exposure defined for those with $A_i=1$ (Smith et al., 2017).

The potential outcome framework was firstly introduced by Neyman (1923) and Rubin (1974). Here, d is dose of the continuous exposure D_i . Let $Y_{ij}(1,d)$ be the potential outcome for the j-th outcome if the i-th individual is exposed with dose d. When unexposed, the dose is undefined but we write the potential outcome simply as $\mathbf{Y}_i(0,0)$ for consistency in notation. We then define the $J \times 1$ vector of potential outcomes $\mathbf{Y}_i(a,d) = \{Y_{i1}(a,d), Y_{i2}(a,d), ..., Y_{iJ}(a,d)\}'$ under a semi-continuous exposure. This enables us to discuss distinct causal effects as follows.

We define the vector of average causal effects corresponding to a one-unit increase in the dose from d to d+1 as given by

$$E \begin{Bmatrix} Y_{i1}(1, d+1) \\ Y_{i2}(1, d+1) \\ \vdots \\ Y_{iJ}(1, d+1) \end{Bmatrix} - E \begin{Bmatrix} Y_{i1}(1, d) \\ Y_{i2}(1, d) \\ \vdots \\ Y_{iJ}(1, d) \end{Bmatrix}$$

among those exposed; we call this the vector of causal dose-response effects. The average causal effect of the binary exposure status requires specification of a reference dose c, which gives the interpretation of the effect as

$$E \begin{Bmatrix} Y_{i1}(1,c) \\ Y_{i2}(1,c) \\ \vdots \\ Y_{iJ}(1,c) \end{Bmatrix} - E \begin{Bmatrix} Y_{i1}(0,0) \\ Y_{i2}(0,0) \\ \vdots \\ Y_{iJ}(0,0) \end{Bmatrix}.$$

This is referred to the causal effect of the exposure status at the reference dose c. In what follows we set c to the mean dose among the exposed, but any positive constant may be chosen as the reference dose.

Identification of the causal effects of a semi-continuous exposure relies on four assumptions: stable unit treatment value assumption (SUTVA), consistency, ignorability, and positivity (Rubin, 1980; Rosenbaum and Rubin, 1983; Rubin, 1990; Cole and Hernán, 2008). The general standard assumptions are extended to a semi-continuous exposure with single outcome setting by Wang et al. (2025). The SUTVA rules out interference between individuals, consistency ensures that the observed multivariate outcome corresponds to the potential outcome under the observed exposure, and ignorability states that, conditional on measured covariates, the exposure status and dose are jointly independent of the potential outcomes. Positivity assumes that each individual has a non-zero probability of either exposure status and a positive density if exposed, any dose given their covariates. The details of these assumptions are described in Appendix A.

2.2 Data generation and exposure models

We assume the data generation model for the response vector \mathbf{Y}_i follows a multivariate linear regression model with a semi-continuous exposure:

$$\begin{pmatrix} Y_{i1} \\ Y_{i2} \\ \vdots \\ Y_{iJ} \end{pmatrix} = \begin{pmatrix} \theta_{01} \\ \theta_{02} \\ \vdots \\ \theta_{0J} \end{pmatrix} + \begin{pmatrix} \theta_{11} \\ \theta_{12} \\ \vdots \\ \theta_{1J} \end{pmatrix} A_{i}(D_{i} - c) + \begin{pmatrix} \theta_{21} \\ \theta_{22} \\ \vdots \\ \theta_{2J} \end{pmatrix} A_{i} + \begin{pmatrix} \theta'_{311} & \theta'_{321} & \theta'_{331} \\ \theta'_{312} & \theta'_{322} & \theta'_{332} \\ \vdots & \vdots & \vdots \\ \theta'_{31J} & \theta'_{32J} & \theta'_{33J} \end{pmatrix} \begin{pmatrix} \mathbf{X}_{i1} \\ \mathbf{X}_{i2} \\ \mathbf{X}_{i3} \end{pmatrix} + \begin{pmatrix} E_{i1} \\ E_{i2} \\ \vdots \\ E_{iJ} \end{pmatrix} \tag{1}$$

where $\mathbf{E}_i = (E_{i1}, E_{i2}, ..., E_{iJ})'$ is a J-dimensional error term assumed to follow a multivariate distribution with mean vector $\mathbf{0}$ and covariance matrix $\mathbf{\Sigma}$ accommodating correlation structure among the J responses with $\boldsymbol{\theta}_0 = (\theta_{01}, \ldots, \theta_{0J})'$, $\boldsymbol{\theta}_1 = (\theta_{11}, \ldots, \theta_{1J})'$, $\boldsymbol{\theta}_2 = (\theta_{21}, \ldots, \theta_{2J})'$, and $\boldsymbol{\theta}_3 = (\boldsymbol{\theta}_{31}, \boldsymbol{\theta}_{32}, \boldsymbol{\theta}_{33})$ where $\boldsymbol{\theta}_{3r} = (\boldsymbol{\theta}_{3r1}, \ldots, \boldsymbol{\theta}_{3rJ})'$ with the coefficients corresponding to \mathbf{X}_{ir} for the j-th outcome for r = 1, 2, 3 and $j = 1, \cdots, J$. Under the assumptions listed in Section 2.1, if the data generation model (1) is correctly specified, $\boldsymbol{\theta}_1$ and $\boldsymbol{\theta}_2$ are of primary interest, as they characterise the causal effects of the semi-continuous exposure across outcomes.

We consider a two-part model for the propensity score with a semi-continuous exposure for the *i*-th individual, consisting of a logistic regression model for the binary exposure status A_i , and a linear model for the dose D_i . Let $S_{i1} = S_i(\mathbf{Z}_{i1}; \boldsymbol{\alpha}_1)$ be the propensity score for the continuous dose, and specify

$$E(D_i|A_i=1,\mathbf{Z}_{i1};\boldsymbol{\alpha}_1) = \bar{\mathbf{Z}}_{i1}'\boldsymbol{\alpha}_1 \tag{2}$$

where $\bar{\mathbf{Z}}_{i1}=(1,\mathbf{Z}'_{i1})'=(1,\mathbf{X}'_{i1},\mathbf{X}'_{i3})'$ and $\boldsymbol{\alpha}_1=(\alpha_{10},\boldsymbol{\alpha}'_{11},\boldsymbol{\alpha}'_{12})'$ with $\boldsymbol{\alpha}_{11}=(\alpha_{111},...,\alpha_{11k_1})'$ and $\boldsymbol{\alpha}_{12}=(\alpha_{121},...,\alpha_{12k_3})'$. For the data generating process, we let W_i denote the error term in (2) where $W_i\perp A_i=1,\mathbf{Z}_{i1}$ and $W_i\sim N(0,\sigma_W^2)$. For the exposure status, we let $S_2(\mathbf{Z}_{i2};\boldsymbol{\alpha}_2)=P(A_i=1|\mathbf{Z}_{i2};\boldsymbol{\alpha}_2)$ be the propensity score, and specify

$$\log \left\{ \frac{S_2(\mathbf{Z}_{i2}; \boldsymbol{\alpha}_2)}{1 - S_2(\mathbf{Z}_{i2}; \boldsymbol{\alpha}_2)} \right\} = \bar{\mathbf{Z}}'_{i2} \boldsymbol{\alpha}_2$$
(3)

where $\bar{\mathbf{Z}}_{i2}=(1,\mathbf{Z}'_{i2})'=(1,\mathbf{X}'_{i2},\mathbf{X}'_{i3})'$ and $\boldsymbol{\alpha}_{2}=(\alpha_{20},\boldsymbol{\alpha}'_{21},\boldsymbol{\alpha}'_{22})'$ with $\boldsymbol{\alpha}_{21}=(\alpha_{211},...,\alpha_{21k_{2}})'$ and $\boldsymbol{\alpha}_{22}=(\alpha_{221},...,\alpha_{22k_{3}})'$.

3 GEE-based two-stage framework with multiple outcomes

3.1 Generalized estimating equations

Consider a two-stage causal analysis for a semi-continuous exposure as describe in Wang et al. (2025) for a single outcome. In Stage I, propensity score regression adjustment mitigates confounding when estimating the dose effect among the exposed. In Stage II, the status effect can be estimated via propensity score regression, inverse probability weighting (IPW), or augmented inverse probability weighting (AIPW). Here, we focus on AIPW due to its doubly robust property. Additional details on alternative Stage II estimators are given in Appendix B.

For each individual i, we observe $\mathcal{D}_i = (\mathbf{Y}_i, \mathbf{X}_i, A_i, D_i)$ for $i = 1, \dots, n$, and the full dataset is denoted by $\mathcal{D} = \{\mathcal{D}_i : i = 1, \dots, n\}$. To estimate the causal effects across the multiple outcomes, we adopt a generalized estimating equation (GEE) approach in both stages (Liang and Zeger, 1986). The GEE framework enables consistent estimation of the marginal effects of the exposure components on each outcome, even when the outcomes within an individual may be correlated. In both stages, we specify a working independence correlation structure for simplicity, which assumes that the multiple outcomes are uncorrelated within an individual in the working model. Although this working assumption does not explicitly model the potential within-subject correlation, use of a robust sandwich variance estimate yields standard errors that are asymptotically valid (Liang and Zeger, 1986; Zeger and Liang, 1986).

In the first stage of estimation, we focus on the causal dose-response effect among exposed. For each outcome Y_{ij} with $j=1,\ldots,J$ and $i=1,\ldots,n$, we model the conditional expectation as

$$E\left\{\begin{pmatrix} Y_{i1} \\ Y_{i2} \\ \vdots \\ Y_{i,I} \end{pmatrix} \middle| A_i = 1, D_i, S_1(\boldsymbol{Z}_{i1}; \boldsymbol{\alpha}_1) \right\} = \begin{pmatrix} \gamma_{101} \\ \gamma_{102} \\ \vdots \\ \gamma_{10,I} \end{pmatrix} + \begin{pmatrix} \gamma_{111} \\ \gamma_{112} \\ \vdots \\ \gamma_{11,I} \end{pmatrix} D_i + \begin{pmatrix} \gamma_{121} \\ \gamma_{122} \\ \vdots \\ \gamma_{12,I} \end{pmatrix} S_1(\boldsymbol{Z}_{i1}; \boldsymbol{\alpha}_1). \tag{4}$$

Let $\gamma_1=(\gamma_{10}',\gamma_{11}',\gamma_{12}')'$ with $\gamma_{10}=(\gamma_{101},\ldots,\gamma_{10J})', \ \gamma_{11}=(\gamma_{111},\ldots,\gamma_{11J})', \ \text{and} \ \gamma_{12}=(\gamma_{121},\ldots,\gamma_{12J})', \ \text{and} \ \phi_1=(\gamma_1',\alpha_1')'.$ The GEE for γ_1 accommodating a propensity score regression adjustment in Stage I is

$$\mathbf{U}_{11}(\mathcal{D}; \boldsymbol{\phi}_1) = \sum_{i=1}^n \mathbf{U}_{i11}(\mathcal{D}_i; \boldsymbol{\phi}_1) = \sum_{i=1}^n A_i \frac{\partial \boldsymbol{\mu}_{i11}(\boldsymbol{\phi}_1)}{\partial \boldsymbol{\gamma}_1} \mathbf{I} \left\{ \mathbf{Y}_i - \boldsymbol{\mu}_{i11}(\boldsymbol{\phi}_1) \right\} = \mathbf{0}$$
 (5)

under a working independence correlation matrix where $\mu_{i11}(\phi_1) = \gamma_{10} + \gamma_{11}D_i + \gamma_{12}S_1(\boldsymbol{Z}_{i1}; \boldsymbol{\alpha}_1)$ and $\boldsymbol{\mathbf{I}}$ is a $J \times J$ identity matrix. The estimating equation for $\boldsymbol{\alpha}_2$ in the exposure model $D|A=1, \boldsymbol{\mathbf{Z}}_{i1}$ is

$$\mathbf{U}_{12}(\mathcal{D}; \boldsymbol{\alpha}_1) = \sum_{i=1}^n \mathbf{U}_{i12}(\mathcal{D}_i; \boldsymbol{\alpha}_1) = \sum_{i=1}^n A_i \frac{\partial \mu_{i12}(\boldsymbol{\alpha}_1)}{\partial \boldsymbol{\alpha}_1} \left\{ D_i - \mu_{i12}(\boldsymbol{\alpha}_1) \right\} = \mathbf{0}$$
 (6)

with $\mu_{i12}(\boldsymbol{\alpha}_1) = \bar{\mathbf{Z}}'_{i1}\boldsymbol{\alpha}_1$.

In Stage II, we focus on the causal effect of the binary exposure. To deal with the fact that the dose of exposure will vary across exposed individuals, we treat $\hat{\gamma}_{11}A_i(D_i-c)$ as an offset term in the Stage II. As described in the penultimate paragraph of this section, estimation is carried out in two steps, so an estimate of γ_{11} will be used. $\hat{\gamma}_{11}A_i(D_i-c)$ is therefore a genuine offset (i.e. a number) at Stage II. Nevertheless to discuss the large sample properties of the resulting estimators, we express the term $\gamma_{11}A_i(D_i-c)$ in terms of the true parameter value. We consider an augmented inverse probability weighted GEE with a working independence assumption

$$\mathbf{U}_{21}(\mathcal{D}; \gamma_1, \phi_2) = \sum_{i=1}^{n} \mathbf{U}_{i21}(\mathcal{D}_i; \gamma_1, \phi_2) = \mathbf{0}$$
(7)

where $\mathbf{U}_{i21}(\mathcal{D}_i; \boldsymbol{\gamma}_1, \boldsymbol{\phi}_2)$ is defined as

$$\sum_{a=0}^{1} w_i\left(a; \boldsymbol{\alpha}_2\right) \frac{\partial \boldsymbol{\mu}_{21}(a; \boldsymbol{\gamma}_2)}{\partial \boldsymbol{\gamma}_2} \mathbf{I} \left[\mathbf{Y}_i - \left[\boldsymbol{\mu}_{21}(a; \boldsymbol{\gamma}_2) + \text{offset} \left\{ \boldsymbol{\gamma}_{11} A_i(D_i - c) \right\} \right] \right] - \left\{ w_i\left(a; \boldsymbol{\alpha}_2\right) - 1 \right\} \boldsymbol{g}_i(a; \boldsymbol{\zeta}, \boldsymbol{\gamma}_2)$$

for a=0,1 with $\pmb{\phi}_2=(\pmb{\gamma}_2',\pmb{\alpha}_2',\pmb{\zeta}'),$ $\pmb{\mu}_{21}\left(a;\pmb{\gamma}_2\right)=\pmb{\gamma}_{20}+\pmb{\gamma}_{21}a$ and

$$w_i\left(a;\boldsymbol{\alpha}_2\right) = \frac{I\left(A_i = a\right)}{S_2\left(\mathbf{Z}_{i2};\boldsymbol{\alpha}_2\right)^a \left\{1 - S_2\left(\mathbf{Z}_{i2};\boldsymbol{\alpha}_2\right)\right\}^{1-a}}$$

for a = 0, 1. Here

$$\boldsymbol{g}_{i}(a;\boldsymbol{\zeta},\boldsymbol{\gamma}_{2}) = \frac{\partial \boldsymbol{\mu}_{21}(a;\boldsymbol{\gamma}_{2})}{\partial \boldsymbol{\gamma}_{2}} \mathbf{I} \left\{ \mathbf{m}_{ia}(\boldsymbol{\zeta}) - \boldsymbol{\mu}_{21}(a;\boldsymbol{\gamma}_{2}) \right\},$$

where $\mathbf{m}_{ia}(\zeta)$ represents the imputation model for those with a=1 or 0 respectively:

$$\mathbf{m}_{ia}(\boldsymbol{\zeta}_a) = E\left\{\mathbf{Y}_i - \boldsymbol{\gamma}_{11}a(D-c)|\mathbf{X}_i; \boldsymbol{\zeta}_a\right\} = \boldsymbol{\zeta}_{a0} + \boldsymbol{\zeta}_{a1}\mathbf{X}_{i1} + \boldsymbol{\zeta}_{a2}\mathbf{X}_{i2} + \boldsymbol{\zeta}_{a3}\mathbf{X}_{i3}$$

with $\zeta_{a0}=(\zeta_{a01},...,\zeta_{a0J})'$ and the $J\times k_r$ coefficient matrices $\zeta_{ar}=(\zeta_{ar1},...,\zeta_{arJ})'$ for r=1,2,3. We let $\zeta_a=\mathrm{vec}(\zeta_{a0},\zeta_{a1},\zeta_{a2},\zeta_{a3})$ and $\zeta=(\zeta_1',\zeta_0')'$. The estimating equation to obtain α_2 in the Stage II propensity score model is

$$\mathbf{U}_{22}(\mathcal{D}; \boldsymbol{\alpha}_2) = \sum_{i=1}^{n} \mathbf{U}_{i22}(\mathcal{D}_i; \boldsymbol{\alpha}_2) = \mathbf{0}$$
(8)

where

$$\mathbf{U}_{i22}\left(\mathcal{D}_{i};\boldsymbol{\alpha}_{2}\right) = \frac{\partial S_{2}(\mathbf{Z}_{i2};\boldsymbol{\alpha}_{2})}{\partial \boldsymbol{\alpha}_{2}} \frac{1}{S_{2}(\mathbf{Z}_{i2};\boldsymbol{\alpha}_{2})\left\{1 - S_{2}(\mathbf{Z}_{i2};\boldsymbol{\alpha}_{2})\right\}} \left\{A_{i} - S_{2}(\mathbf{Z}_{i2};\boldsymbol{\alpha}_{2})\right\}.$$

To obtain ζ we consider this estimating equation

$$\mathbf{U}_{23}(\mathcal{D}; \boldsymbol{\gamma}_1, \boldsymbol{\zeta}) = \sum_{i=1}^n \mathbf{U}_{i23}(\mathcal{D}_i; \boldsymbol{\gamma}_1, \boldsymbol{\zeta})$$
(9)

where $\mathbf{U}_{i23}(\mathcal{D}_i; \boldsymbol{\gamma}_1, \boldsymbol{\zeta}) = \left\{ \mathbf{U}_{i231}'(\mathcal{D}_i; \boldsymbol{\gamma}_1, \boldsymbol{\zeta}_1), \mathbf{U}_{i232}'(\mathcal{D}_i; \boldsymbol{\zeta}_0) \right\}'$ with

$$\mathbf{U}_{i231}\left(\mathcal{D}_{i};\boldsymbol{\gamma}_{1},\boldsymbol{\zeta}_{1}\right)=A_{i}\frac{\partial\mathbf{m}_{i1}\left(\boldsymbol{\zeta}_{1}\right)}{\partial\boldsymbol{\zeta}_{1}}\mathbf{I}\left\{\mathbf{Y}_{i}-\boldsymbol{\gamma}_{11}(D_{i}-c)-\mathbf{m}_{i1}\left(\boldsymbol{\zeta}_{1}\right)\right\}$$

and

$$\mathbf{U}_{i232}\left(\mathcal{D}_{i};\boldsymbol{\zeta}_{0}\right)=\left(1-A_{i}\right)\frac{\partial\mathbf{m}_{i0}\left(\boldsymbol{\zeta}_{0}\right)}{\partial\boldsymbol{\zeta}_{0}}\mathbf{I}\left\{\mathbf{Y}_{i}-\mathbf{m}_{i0}(\boldsymbol{\zeta}_{0})\right\}$$

specified under a working independence assumption. By combining (5), (6), (8) (7), and (9) the joint estimating equation for the corresponding two-stage approach is

$$\mathbf{U}(\mathbf{\Omega}) = \sum_{i=1}^{n} \mathbf{U}_i(\mathbf{\Omega}) = \mathbf{0}$$
 (10)

where

$$\mathbf{U}_{i}(\mathbf{\Omega}) = \left\{ egin{array}{l} \mathbf{U}_{i1}\left(\mathcal{D};oldsymbol{\phi}_{1}
ight) \ \mathbf{U}_{i2}\left(\mathcal{D};oldsymbol{\gamma}_{1},oldsymbol{\phi}_{2}
ight) \end{array}
ight\} = \mathbf{0}$$

with $\mathbf{U}_{i1}(\mathcal{D}_i; \phi_1) = \{\mathbf{U}'_{i11}(\mathcal{D}_i; \phi_1), \mathbf{U}'_{i12}(\mathcal{D}_i; \alpha_1)\}'$ and $\mathbf{U}_{i2}(\mathcal{D}_i; \gamma_1, \phi_2) = \{\mathbf{U}'_{i21}(\mathcal{D}_i; \gamma_1, \phi_2), \mathbf{U}'_{i22}(\mathcal{D}_i; \alpha_2), \mathbf{U}'_{i23}(\mathcal{D}_i; \gamma_1, \zeta)\}'$. Solving the joint estimating equation (10) yields the estimated causal dose-response effect and the estimated causal effect of the binary exposure versus no exposure. In practice, estimation is carried out sequentially: the Stage I estimating equation is solved to obtain $\hat{\phi}_1$ and thereby $\hat{\gamma}_{11}$, which represents the estimated causal dose-response effect. $\hat{\gamma}_{11}$ is then substituted into the Stage II equations to yield $\hat{\phi}_2$, including $\hat{\gamma}_{21}$, the estimated causal effect of exposure at the reference dose versus no exposure. See Wang et al. (2025) for the detailed estimation procedure.

Here we establish the large-sample behaviour of the two-stage estimator described above. Let $\hat{\Omega} = (\hat{\phi}_1', \hat{\phi}_2')'$ denote the solution to the joint estimating equation (10), where $\mathbf{U}_i(\cdot)$ is the contribution for individual i ($i=1,\ldots,n$) and Ω collects all unknown components defined in Section 3.1.

We use the empirical sandwich estimator, replacing expectations in $\mathcal{A}(\cdot)$ and $\mathcal{B}(\cdot)$ with their sample analogues to obtain $\hat{\Sigma}(\hat{\Omega})$. This yields standard errors, Wald tests, and confidence intervals for all components of $\hat{\Omega}$; see Wang et al. (2025) for further details.

3.2 Large sample properties

We now establish the large sample properties of the estimators under the two-stage analysis described above. Let $\Omega = (\phi_1', \phi_2')', \hat{\Omega} = (\hat{\phi}_1', \hat{\phi}_2')'$ denote the solution to (10), and $\mathbf{U}_i(\cdot)$ be the estimating function for individual i with $i=1,\ldots,n$. Under the assumptions in Section 2.1, if the Stage I propensity score $S_1(\mathbf{Z}_1; \alpha_1)$ is correctly specified, then $\hat{\phi}_1$ is consistent for θ_{11} , the causal dose–response effect in (1). Moreover, if $\hat{\phi}_1$ is consistent to θ_{11} and at least one of the Stage II propensity score model $S_2(\mathbf{Z}_2; \alpha_2)$ or the imputation model $\mathbf{m}_a(\theta)$ is correctly specified, then $\hat{\phi}_2$ is consistent for θ_2 , the causal effect of exposure at the reference dose versus no exposure in (1). Full statements and proofs are provided in Appendix C.

Theorem 1 (Asymptotic normality) Under assumptions listed in Section 2.1 and standard regularity conditions (Van der Vaart, 2000), the joint estimator $\hat{\Omega}$ is consistent for Ω , and

$$\sqrt{n}(\hat{\Omega} - \Omega) \stackrel{d}{\to} N(0, \Sigma(\Omega)),$$

where

$$\Sigma(\Omega) = \mathcal{A}^{-1}(\Omega) \, \mathcal{B}(\Omega) \, \{\mathcal{A}^{-1}(\Omega)\}',$$
 with $\mathcal{A}(\Omega) = E \, \{-\partial \mathbf{U}_i(\Omega)/\partial \Omega'\}$ and $\mathcal{B}(\Omega) = E \, \{\mathbf{U}_i(\Omega)\mathbf{U}_i(\Omega)'\}.$

For variance estimation, we employ the empirical sandwich estimator obtained by replacing population expectations in $\mathcal{A}(\cdot)$ and $\mathcal{B}(\cdot)$ with their sample counterparts. The resulting covariance matrix $\hat{\Sigma}(\hat{\Omega})$ provides standard errors for all components of $\hat{\Omega}$, from which Wald tests and confidence intervals can be constructed. Derivations are provided in Section 3 of Supplementary Material.

4 Homogeneity tests of causal effects

We consider three tests to assess evidence against the homogeneity of effects: homogeneity tests are for the causal dose-response effects, and causal effects of exposure status; a global test that jointly tests both is also considered. They serve as tools for assessing heterogeneity in exposure—outcome associations across outcomes within the proposed two-stage framework. Our discussion focuses on the setting with PS regression adjustment in Stage I and AIPW in Stage II; other specifications can be accommodated in the same way.

4.1 Testing for the causal dose-response effect

Here we aim to test the null hypothesis of homogeneity of the dose-response effects across the J outcomes:

$$H_0: \gamma_{111} = \gamma_{112} = \cdots = \gamma_{11J}.$$

To conduct the test, we reparameterize the model in (4) according to

$$\gamma_{10j} = \gamma_{101} + \delta_{10j}, \quad \gamma_{11j} = \gamma_{111} + \delta_{11j}, \quad \gamma_{12j} = \gamma_{121} + \delta_{12j}, \quad j = 2, \dots, J,$$

where δ_{10j} , δ_{11j} , and δ_{12j} represent the deviations from the first outcome for the intercept, the effect of the dose, and the propensity score covariate adjustment respectively. For identifiability, we set $\delta_{101} = \delta_{111} = \delta_{121} = 0$. Then, (4) can then be expressed as

$$E\{\mathbf{Y}_{i}|A_{i}=1,D_{i},S_{1}(\mathbf{Z}_{i1};\boldsymbol{\alpha}_{1});\boldsymbol{\gamma}_{1}\}=\boldsymbol{\gamma}_{10}+\boldsymbol{\gamma}_{11}D_{i}+\boldsymbol{\gamma}_{12}S_{1}(\mathbf{Z}_{i1};\boldsymbol{\alpha}_{1}),$$

where $\gamma_{10}=(\gamma_{101},\gamma_{101}+\delta_{102},\ldots,\gamma_{101}+\delta_{10J})',$ $\gamma_{11}=(\gamma_{111},\gamma_{111}+\delta_{112},\ldots,\gamma_{111}+\delta_{11J})',$ and $\gamma_{12}=(\gamma_{121},\gamma_{121}+\delta_{122},\ldots,\gamma_{121}+\delta_{12J})'.$ Under this parameterization, testing the original null hypothesis $H_0:\gamma_{111}=\ldots=\gamma_{11J}$ is equivalent to testing

$$H_0: \delta_{112} = \cdots = \delta_{11I} = 0.$$

The vector $\delta_{11} = (\delta_{112}, \dots, \delta_{11J})'$ is a vector of differences of between elements of γ_{11} , and $\hat{\delta}_{11}$ follows a multivariate normal distribution with mean zero and the covariance matrix $\Sigma_{\delta_{11}}$ which can be consistently estimated using the Delta method (Doob, 1935). Specifically δ_{11} can be written as $\delta_{11} = \mathbf{R}\gamma_{11}$, where \mathbf{R} is a $(J-1)\times J$ contrast matrix defined as

$$\mathbf{R} = \begin{pmatrix} -1 & 1 & 0 & \dots & 0 \\ -1 & 0 & 1 & \dots & 0 \\ \vdots & \vdots & \vdots & \ddots & \vdots \\ -1 & 0 & 0 & \dots & 1 \end{pmatrix}. \tag{11}$$

The covariance matrix of $\hat{\delta}_{11}$ is estimated as

$$\hat{\Sigma}_{\boldsymbol{\delta}_{11}} = \mathbf{R}\,\widehat{\mathrm{cov}}(\hat{\boldsymbol{\gamma}}_{11})\,\mathbf{R}',$$

where $\widehat{\text{cov}}(\hat{\gamma}_{11})$ is the estimated asymptotic covariance matrix of $\hat{\gamma}_{11}$. Here, the covariance matrix of $\hat{\gamma}_{11}$ can be obtained by extracting the corresponding subblock from $\hat{\Sigma}(\hat{\Omega})$ derived in Section 3.2. Based on the asymptotic normality of δ_{11} , the Wald test statistic is constructed as

$$\Lambda_1 = oldsymbol{\delta}_{11}' \, \hat{oldsymbol{\Sigma}}_{oldsymbol{\delta}_{11}}^{-1} oldsymbol{\delta}_{11},$$

which follows an asymptotic chi-squared distribution with J-1 degrees of freedom under the null hypothesis. There is an evidence to reject the null hypothesis $H_0: \delta_{112} = \ldots = \delta_{11J} = 0$ if the test statistic Λ_1 exceeds the critical value $\chi^2_{J-1,1-\psi}$ where ψ is the pre-specified significance level.

4.2 Testing for the causal effect of exposure status

Pooling information across outcomes can sharpen inference, but only if effects are homogeneous; accordingly, we therefore aim to test the homogeneity of the binary exposure effect across the J outcomes, here under the AIPW framework. To account for the dose-response effect estimated in Stage I, we incorporate $\hat{\gamma}_{11}A(D-c)$ as an offset term. We reparameterize the Stage II marginal structural model as follows:

$$\gamma_{20} = (\gamma_{201}, \gamma_{201} + \delta_{202}, \dots, \gamma_{201} + \delta_{20J})', \gamma_{21} = (\gamma_{211}, \gamma_{211} + \delta_{212}, \dots, \gamma_{211} + \delta_{21J})',$$

where δ_{20j} and δ_{21j} are the deviations from the first outcome (j=1). Then the original null hypothesis of homogeneity of the binary exposure effect

$$H_0: \gamma_{211} = \gamma_{212} = \cdots = \gamma_{21J}$$

is equivalent to testing

$$H_0: \delta_{212} = \cdots = \delta_{21I} = 0.$$

The corresponding vector is denoted as $\delta_{21} = (\delta_{212}, \dots, \delta_{21J})'$. By the asymptotic normality of $\hat{\gamma}_{21}$, $\hat{\delta}_{21}$ follows an asymptotic multivariate normal distribution with mean zero and covariance matrix $\Sigma_{\delta_{21}}$. Similarly, $\Sigma_{\delta_{21}}$ can be consistently estimated using the Delta method (Doob, 1935). We can write $\delta_{21} = \mathbf{R}\gamma_{21}$, and the covariance matrix can be estimated by

$$\widehat{\mathbf{\Sigma}}_{\boldsymbol{\delta}_{21}} = \mathbf{R}\,\widehat{\text{cov}}(\widehat{\boldsymbol{\gamma}}_{21})\,\mathbf{R}',$$

where $\widehat{\text{cov}}(\hat{\gamma}_{21})$ is the estimated asymptotic covariance matrix of $\hat{\gamma}_{21}$, which can be extracted from the corresponding block of the joint covariance matrix $\widehat{\Sigma}(\hat{\Omega})$ obtained in Section 3.2. Based on the asymptotic normality of δ_{21} , the Wald test statistic is constructed as

$$\Lambda_2 = oldsymbol{\delta}_{21}' \, \widehat{oldsymbol{\Sigma}}_{oldsymbol{\delta}_{21}}^{-1} oldsymbol{\delta}_{21},$$

which follows an asymptotic chi-squared distribution with J-1 degrees of freedom under the null hypothesis. The null hypothesis $H_0: \delta_{212} = \ldots = \delta_{21J} = 0$ is rejected if the test statistic Λ_2 is greater than the critical value $\chi^2_{J-1,1-\psi}$.

4.3 A global test of homogeneity across outcomes and exposures

To simultaneously assess the homogeneity of both the continuous and binary exposure effects across the J outcomes, we propose a global homogeneity test that jointly tests the deviation parameters for both components. Specifically, the global null hypothesis can be stated as

$$H_0: \delta_{112} = \ldots = \delta_{11J} = 0$$
 and $\delta_{212} = \ldots = \delta_{21J} = 0$.

Here δ_{11} and δ_{21} are two vectors of deviations for the continuous and binary exposure effects respectively. We define the combined deviation vector as $\boldsymbol{\delta}=(\delta'_{11},\delta'_{21})'$, and asymptotically it is distributed as multivariate normal with mean zero and covariance matrix $\Sigma_{\boldsymbol{\delta}}$ where

$$\widehat{oldsymbol{\Sigma}}_{oldsymbol{\delta}} = \mathbf{R}_g \, \widehat{\mathrm{cov}} \left\{ egin{pmatrix} \hat{oldsymbol{\gamma}}_{11} \ \hat{oldsymbol{\gamma}}_{21} \end{pmatrix}
ight\} \mathbf{R}_g',$$

with \mathbf{R}_q is a $2(J-1) \times 2J$ block-diagonal contrast matrix defined as

$$\mathbf{R}_g = egin{pmatrix} \mathbf{R} & \mathbf{0} \ \mathbf{0} & \mathbf{R} \end{pmatrix}$$

with R given by (11). The joint covariance matrix $\widehat{\text{cov}}\left\{(\hat{\gamma}'_{11}, \hat{\gamma}'_{21})'\right\}$ can be obtained by extracting the relevant block from $\widehat{\Sigma}(\widehat{\Omega})$ derived in Section 3.2. The Wald test statistic for the global homogeneity test is

$$\Lambda_3 = \boldsymbol{\delta}' \, \widehat{\boldsymbol{\Sigma}}_{\boldsymbol{\delta}}^{-1} \boldsymbol{\delta},$$

and it follows a chi-squared distribution with 2(J-1) degrees of freedom under the null hypothesis. The global null hypothesis is rejected if the test statistic Λ_3 exceeds the critical value $\chi^2_{2(J-1),1-\psi}$.

5 Simulation studies

5.1 The data generation process

Here we report on simulation studies conducted to assess the performance of the proposed two-stage methods of estimation under various scenarios. We consider sample sizes of n=500 and n=2000 with 2000 replications for each scenario. We set the number of outcomes to J=3. The 6-dimensional covariate vector $\mathbf{X}=(X_{11},X_{12},X_{21},X_{22},X_{31},X_{32})'$ is generated from a multivariate normal distribution with mean zero and covariance matrix $\mathbf{\Sigma}_X$ with diagonal elements set to 1 and off-diagonal elements set to 0.2.

The binary exposure A is generated from (3) where $\bar{\mathbf{Z}}_2 = (1, X_{21}, X_{22}, X_{31}, X_{32})'$ and $\alpha_2 = (\alpha_{20}, \log 1.2, \log 2, \log 0.8, \log 1.3)'$. We solve for α_{20} so that P(A=1)=0.5 yielding $\alpha_{20}=0.0008$. The continuous exposure D is generated from (2) where $\bar{\mathbf{Z}}_1 = (1, X_{11}, X_{12}, X_{31}, X_{32})'$ and $\alpha_1 = (0, 1, 0.5, 0.6, 0.8)'$ with $W \sim N(0,1)$. The outcome vector $\mathbf{Y} = (Y_1, Y_2, Y_3)'$ is generated from model (1) with $\boldsymbol{\theta}_0 = \mathbf{0}$, $\boldsymbol{\theta}_{1j} = 2\Gamma_1^{j-1}$, $\boldsymbol{\theta}_{2j} = 2\Gamma_2^{j-1}$ for j = 1, 2, 3, $\boldsymbol{\theta}_{311} = (2, 2)'$, $\boldsymbol{\theta}_{312} = (1, 1)'$, $\boldsymbol{\theta}_{313} = (0.5, 0.5)'$, $\boldsymbol{\theta}_{321} = \boldsymbol{\theta}_{322} = \boldsymbol{\theta}_{323} = (0.5, 0.5)'$, $\boldsymbol{\theta}_{331} = (1, 1)'$, $\boldsymbol{\theta}_{332} = (0.5, 0.5)'$, and $\boldsymbol{\theta}_{333} = (0.25, 0.25)'$. The setting where $\Gamma_1 = \Gamma_2 = 1$ represents the scenario with common exposure effects across all outcomes. The error vector $\mathbf{E} = (E_1, E_2, E_3)'$ follows a multivariate normal distribution with variance $\mathrm{Var}(E_j) = 1$ and correlation structure $\mathrm{Corr}(E_j, E_l) = 0.4^{|j-l|}$.

5.2 Evaluation of two-stage approach

5.2.1 Methods

We evaluate the proposed two-stage methods by comparing four estimation approaches for the causal effects of the continuous and binary components of the semi-continuous exposure. Specifically, we consider the following methods:

- (1) fitting the data generation model;
- (2) applying PS regression adjustment at both stages;
- (3) applying PS regression adjustment in Stage I combined with IPW in Stage II;
- (4) applying PS regression adjustment in Stage I combined with AIPW in Stage II.

In this subsection, we focus on the setting where the exposure effects are common across outcomes with $\Gamma_1 = \Gamma_2 = 1$. To investigate the robustness of the two-stage approach with AIPW in Stage II under model misspecification, we explore several scenarios:

- (A) misspecification of the Stage I PS model (S_1) , where X_{12} is omitted from S_1 ;
- (B) misspecification of the Stage II PS model (S_2) , where X_{22} is omitted from S_2 ;
- (C) misspecification of the imputation model in Stage II for Method 4, where the imputation models are simplified to exclude X_{22} , resulting in $\mathbf{m}_a(\mathbf{X}) = \boldsymbol{\zeta}_{a0} + \boldsymbol{\zeta}_{a11}X_{11} + \boldsymbol{\zeta}_{a12}X_{12} + \boldsymbol{\zeta}_{a21}X_{21} + \boldsymbol{\zeta}_{a31}X_{31} + \boldsymbol{\zeta}_{a32}X_{32}$ for a = 0, 1;
- (D) misspecification of both the S_1 model and the imputation model, combining scenarios A and C;
- (E) misspecification of both the S_2 model and the imputation model, combining scenarios B and C.

These scenarios are designed to assess the impact of misspecification of each model.

5.2.2 Results

Table 1: Empirical performance of estimators for causal effects under homogeneous exposure effects with $\Gamma_1 = \Gamma_2 = 1$

| _ 1 _ 1 | | | | | | | | | |
|------------|---|---------|-------|--------------|--------------|-----------|-----------|-------|--------|
| | | | | = <u>500</u> | | | | 2000 | |
| Method | j | Ebias | ESE | ERSE | ECP(%) | Ebias | ESE | ERSE | ECP(%) |
| | | | | Stage | I: Continuo | us exposu | re effect | | |
| | 1 | < 0.001 | 0.039 | 0.038 | 94.5 | < 0.001 | 0.019 | 0.019 | 95.1 |
| DG model | 2 | < 0.001 | 0.039 | 0.038 | 94.8 | < 0.001 | 0.019 | 0.019 | 94.4 |
| | 3 | -0.001 | 0.038 | 0.038 | 95.2 | < 0.001 | 0.019 | 0.019 | 94.8 |
| | 1 | -0.002 | 0.077 | 0.076 | 94.6 | < 0.001 | 0.038 | 0.038 | 94.8 |
| PS_{l} | 2 | 0.001 | 0.078 | 0.076 | 93.7 | < 0.001 | 0.038 | 0.038 | 94.4 |
| | 3 | -0.001 | 0.076 | 0.076 | 94.1 | < 0.001 | 0.038 | 0.038 | 94.2 |
| | | | | Stag | e II: Binary | exposure | effect | | |
| | 1 | -0.006 | 0.097 | 0.096 | 94.9 | < 0.001 | 0.047 | 0.048 | 95.9 |
| DG model | 2 | -0.004 | 0.097 | 0.096 | 94.4 | < 0.001 | 0.048 | 0.048 | 94.6 |
| | 3 | < 0.001 | 0.094 | 0.096 | 95.3 | < 0.001 | 0.047 | 0.048 | 95.6 |
| | 1 | -0.004 | 0.303 | 0.299 | 93.7 | 0.003 | 0.142 | 0.144 | 95.5 |
| PS_{II} | 2 | -0.002 | 0.174 | 0.168 | 94.1 | < 0.001 | 0.082 | 0.084 | 95.4 |
| | 3 | 0.002 | 0.120 | 0.120 | 95.3 | < 0.001 | 0.058 | 0.060 | 95.4 |
| | 1 | -0.003 | 0.325 | 0.310 | 93.6 | 0.003 | 0.152 | 0.154 | 95.0 |
| IPW_{II} | 2 | < 0.001 | 0.189 | 0.181 | 93.5 | < 0.001 | 0.090 | 0.090 | 95.3 |
| | 3 | 0.003 | 0.132 | 0.129 | 94.7 | < 0.001 | 0.063 | 0.064 | 94.9 |
| | 1 | -0.005 | 0.102 | 0.101 | 95.0 | < 0.001 | 0.049 | 0.050 | 95.6 |
| $AIPW_II$ | 2 | -0.002 | 0.102 | 0.101 | 94.1 | < 0.001 | 0.050 | 0.050 | 95.1 |
| | 3 | 0.002 | 0.099 | 0.100 | 95.9 | < 0.001 | 0.049 | 0.050 | 95.7 |
| | | | | | | | | | |

PS_I: Using PS regression adjustment in Stage I; IPW_{II}: Using IPW in Stage II; AIPW_{II}: Using AIPW in Stage II.

Table 1 presents the empirical performance of the estimators under the scenario of homogeneous exposure effects with $\Gamma_1 = \Gamma_2 = 1$. Across all methods, the estimators give small empirical bias, with the empirical standard errors (ESE) and empirical robust standard errors (ERSE) closely aligned and empirical coverage probabilities (ECP) close to the nominal 95%. As expected, the covariate regression adjustment approach demonstrates the smallest variance, confirming it as the most efficient method when the data generation (DG) model is correctly specified. In contrast, the IPW approach shows the largest variance due to the relative instability of weighting. The AIPW approach achieves lower variance than both the IPW and PS regression methods by combining information from the DG model and the propensity scores. Additionally, as the sample size increases from 500 to 2000, the variances of the estimators consistently decrease across all methods. The empirical coverage probabilities also remain stable and close to the nominal 95% level in both settings. Overall, these results confirm the good performance of all methods under correctly specified models with homogeneous effects.

Table 2: Empirical results for estimators of causal effects for the two-stage approach with AIPW in Stage II under various model misspecifications with $\Gamma_1 = \Gamma_2 = 1$

| <u> </u> | | uii | 1 - 12 - | | = 500 | | | n = | 2000 | |
|---|----------|-----|----------|-------|-------|--------|---------|-------|-------|--------|
| Misspecified Model | Exposure | j | Ebias | ESE | ERSE | ECP(%) | Ebias | ESE | ERSE | ECP(%) |
| | | 1 | 0.784 | 0.132 | 0.124 | 0.0 | 0.785 | 0.061 | 0.062 | 0.0 |
| | D | 2 | 0.416 | 0.090 | 0.088 | 0.5 | 0.413 | 0.044 | 0.044 | 0.0 |
| C | | 3 | 0.228 | 0.077 | 0.075 | 14.2 | 0.228 | 0.038 | 0.038 | 0.0 |
| S_1 | | 1 | -1.998 | 0.127 | 0.126 | 0.0 | -2.002 | 0.063 | 0.063 | 0.0 |
| | A | 2 | -1.999 | 0.096 | 0.095 | 0.0 | -2.002 | 0.047 | 0.048 | 0.0 |
| | | 3 | -2.000 | 0.095 | 0.097 | 0.0 | -1.998 | 0.049 | 0.048 | 0.0 |
| | | 1 | -0.002 | 0.077 | 0.076 | 94.6 | < 0.001 | 0.038 | 0.038 | 94.8 |
| | D | 2 | 0.001 | 0.078 | 0.076 | 93.7 | < 0.001 | 0.038 | 0.038 | 94.4 |
| C | | 3 | -0.001 | 0.076 | 0.076 | 94.1 | < 0.001 | 0.038 | 0.038 | 94.2 |
| S_2 | | 1 | -0.006 | 0.099 | 0.099 | 95.0 | < 0.001 | 0.048 | 0.049 | 95.5 |
| | A | 2 | -0.003 | 0.100 | 0.099 | 94.3 | < 0.001 | 0.048 | 0.049 | 95.3 |
| | | 3 | 0.001 | 0.096 | 0.099 | 95.8 | < 0.001 | 0.049 | 0.049 | 95.9 |
| | | 1 | -0.002 | 0.077 | 0.076 | 94.6 | < 0.001 | 0.038 | 0.038 | 94.8 |
| | D | 2 | 0.001 | 0.078 | 0.076 | 93.7 | < 0.001 | 0.038 | 0.038 | 94.4 |
| $\mathbf{m}_a(\mathbf{X};oldsymbol{	heta})$ | | 3 | -0.001 | 0.076 | 0.076 | 94.1 | < 0.001 | 0.038 | 0.038 | 94.2 |
| $\mathbf{m}_a(\mathbf{A}, \mathbf{o})$ | | 1 | -0.002 | 0.103 | 0.106 | 96.0 | 0.002 | 0.049 | 0.053 | 96.4 |
| | A | 2 | 0.001 | 0.103 | 0.106 | 94.7 | < 0.001 | 0.051 | 0.053 | 95.9 |
| | | 3 | 0.006 | 0.010 | 0.106 | 96.4 | < 0.001 | 0.050 | 0.053 | 96.2 |
| | | 1 | 0.784 | 0.132 | 0.124 | 0.0 | 0.785 | 0.061 | 0.062 | 0.0 |
| | D | 2 | 0.416 | 0.090 | 0.088 | 0.5 | 0.413 | 0.044 | 0.044 | 0.0 |
| $S_1 + \mathbf{m}_a(\mathbf{X}; \boldsymbol{\theta})$ | | 3 | 0.228 | 0.077 | 0.075 | 14.2 | 0.228 | 0.038 | 0.038 | 0.0 |
| | A | 1 | -2.000 | 0.129 | 0.127 | 0.0 | -2.003 | 0.064 | 0.064 | 0.0 |
| | | 3 | -2.001 | 0.098 | 0.096 | 0.0 | -2.002 | 0.048 | 0.049 | 0.0 |
| | | 2 | -2.000 | 0.095 | 0.097 | 0.0 | -1.998 | 0.049 | 0.048 | 0.0 |
| | D | 1 | -0.002 | 0.077 | 0.076 | 94.6 | < 0.001 | 0.038 | 0.038 | 94.8 |
| | | 2 | 0.001 | 0.078 | 0.076 | 93.7 | < 0.001 | 0.038 | 0.038 | 94.4 |
| $S_2 + \mathbf{m}_a(\mathbf{X}; \boldsymbol{\theta})$ | | 3 | -0.001 | 0.076 | 0.076 | 94.1 | < 0.001 | 0.038 | 0.038 | 94.2 |
| $D_2 + \mathbf{m}_a(\mathbf{A}, 0)$ | | 1 | -0.149 | 0.107 | 0.119 | 78.2 | -0.145 | 0.052 | 0.059 | 28.4 |
| | A | 2 | -0.093 | 0.103 | 0.108 | 88.0 | -0.093 | 0.050 | 0.054 | 59.9 |
| | | 3 | -0.063 | 0.098 | 0.105 | 92.5 | -0.066 | 0.050 | 0.052 | 76.6 |

 S_1 represents the propensity score model for the binary exposure A, given by $S_1 = E(A|\mathbf{Z}_1)$; S_2 represents the propensity score model for the continuous exposure D conditioned on A=1, given by $S_2 = E(D|A=1,\mathbf{Z}_2)$; $\mathbf{m}_a(\mathbf{X};\boldsymbol{\theta})$ represents the imputation models for a=0,1.

Table 2 reports the empirical findings from applying PS regression in Stage I and AIPW in Stage II under various types of model misspecifications. When only the PS model S_2 of the binary exposure is misspecified, the estimator remains robust for both the continuous and binary exposure effects, with small bias, standard errors closely matching ERSEs, and ECP near 95%. This demonstrates the double robustness property where the outcome imputation model compensates for the misspecification of S_2 . Similarly, when only the imputation model $\mathbf{m}_a(\mathbf{X};\boldsymbol{\zeta})$ is misspecified, the estimator continues to perform well due to the correct specification of the PS models. In contrast, when the PS model S_1 in Stage I is misspecified, the estimators are biased for both the continuous and binary exposure effects; the ECP can be as low as zero. When both S_2 and $\mathbf{m}_a(\mathbf{X};\boldsymbol{\zeta})$ are misspecified, the estimation of the continuous exposure effect has negligible bias, while the binary exposure effect exhibits bias and a reduction in coverage probabilities. However, when S_1 and $\mathbf{m}_a(\mathbf{X};\boldsymbol{\zeta})$ are misspecified, the estimators are biased with extreme bias and ECP approaching zero in some cases.

These findings highlight the importance of the correct specification of S_1 for consistent estimation. If S_1 is correctly specified, then AIPW in Stage II can still provide consistent results under misspecification of either S_2 or $\mathbf{m}_a(\mathbf{X}; \boldsymbol{\zeta})$. We also consider these model misspecifications when PS regression and IPW is used in Stage II; the results are given in Section 4 of Supplementary Material. The results indicate that correct specification of both propensity scores ensures the consistent estimated causal effects in both stages.

Table 3: Empirical Rejection Rates for Continuous, Binary, and Global Homogeneity Tests across Different Combinations of Γ_1 and Γ_2 Values, Sample Sizes, and Estimation Methods

| $ \begin{array}{c ccccccccccccccccccccccccccccccccccc$ | | | | | | | | Homogene | ity Tests: I | Homogeneity Tests: Rejection Rates (% | (%) Se | | | | |
|--|------------|------------|------------------------------------|------------|--------|--------|------------|----------|--------------|---------------------------------------|--------|--------|------------|--------|--------|
| Fig. Method Continuous Binary Global Continuous Binary Clobal Clo | | | | u | | | 7. | | | u | = 1000 | | u | = 2000 | |
| PSH PSM PSM PSM PSM PSM PSM PSM PSM PSM PSM PSM | Γ_1 | Γ_2 | Method | Continuous | Binary | Global | Continuous | Binary | Global | Continuous | Binary | Global | Continuous | Binary | Global |
| PSi + PSi PSi + PSi + PSi PSi + PSi | | | DG model | 6.50 | 7.00 | 7.50 | 5.55 | 2.60 | 6.25 | 5.15 | 5.20 | 2.60 | 5.60 | 5.40 | 6.25 |
| PS + PWIII 7.80 | - | + | $PS_I + PS_{II}$ | 7.80 | 5.80 | 7.45 | 6.30 | 5.55 | 6.50 | 2.00 | 5.45 | 5.95 | 5.55 | 5.55 | 5.05 |
| PSi + AlPWii 7.80 7.80 8.45 6.30 6.00 7.00 5.00 5.85 5.85 5.55 5.55 | _ | _ | $PS_I + IPW_{II}$ | 7.80 | 6.30 | 7.75 | 6.30 | 5.50 | 6.55 | 2.00 | 5.45 | 5.85 | 5.55 | 5.80 | 5.30 |
| DG model 7.10 99.95 99.90 5.90 100.00 100.00 5.45 100.00 100.00 445 100.00 100.00 PS, | | | + | 7.80 | 7.80 | 8.45 | 6.30 | 00.9 | 7.00 | 2.00 | 5.85 | 5.92 | 5.55 | 5.52 | 5.40 |
| 1.2 PS; + PS; 6.00 84.85 78.65 6.50 96.05 92.60 4.95 99.95 99.85 5.05 100.00 PS; + PS; 6.00 98.25 99.85 6.50 94.70 90.05 4.95 99.95 99.60 5.05 100.00 PS; + PIPWii 6.00 99.85 99.85 6.50 94.70 90.05 4.95 99.00 99.00 5.05 100.00 PS; + PS; + PS; 7.05 100.00 100.00 6.25 100.00 100.00 5.25 100.00 100.00 PS; + PS; 7.05 100.00 100.00 6.40 100.00 100.00 5.30 100.00 100.00 4.50 100.00 PS; + PS; | | | DG model | 7.10 | 99.95 | 99.90 | 5.90 | 100.00 | 100.00 | 5.45 | 100.00 | 100.00 | 4.45 | 100.00 | 100.00 |
| PSi + IPWii 6.00 82.20 75.85 6.50 94.70 90.05 4.95 99.90 99.60 5.05 100.00 PSi + AIPWii 6.00 99.85 99.85 6.50 100.00 100.00 4.95 100.00 100.00 5.05 100.00 PSi + PSii 7.05 100.00 100.00 6.45 100.00 100.00 5.30 100.00 100.00 4.50 100.00 PSi + PSii 7.05 100.00 100.00 6.40 100.00 100.00 5.30 100.00 100.00 4.50 100.00 PSi + PSii 7.05 100.00 100.00 6.40 100.00 100.00 5.30 100.00 100.00 4.50 100.00 PSi + PSii 7.05 100.00 100.00 6.40 100.00 100.00 5.30 100.00 4.50 100.00 PSi + PSii 93.05 5.40 88.25 98.85 5.50 97.35 100.00 5.20 100.00 5.20 100.00 PSi + PSii 93.05 5.40 88.25 98.85 5.50 97.40 100.00 5.70 100.00 5.20 100.00 PSi + PSii 100.00 6.40 100.00 100.00 5.70 100.00 5.70 100.00 5.20 PSi + PSii 100.00 6.40 100.00 100.00 5.70 100.00 5.70 100.00 5.20 PSi + PSii 100.00 6.40 100.00 100.00 100.00 4.75 100.00 5.20 5.00 PSi + PSii 100.00 6.55 100.00 100.00 4.85 100.00 5.20 100.00 5.20 PSi + PSii 100.00 6.55 100.00 100.00 4.75 100.00 100.00 5.40 PSi + PSii 100.00 6.55 100.00 100.00 4.85 100.00 4.85 100.00 100.00 4.85 PSi + PSii 100.00 6.55 100.00 100.00 100.00 4.25 100.00 100.00 4.85 PSi + PSii 94.60 88.35 99.40 98.70 94.70 100.00 100.00 100.00 100.00 100.00 100.00 PSi + PSii 100.00 | - | 4 | $PS_I + PS_{II}$ | 00.9 | 84.85 | 78.65 | 6.50 | 96.05 | 92.60 | 4.95 | 99.95 | 99.85 | 5.05 | 100.00 | 100.00 |
| PSi + AlPW 6.00 99.85 99.85 6.50 100.00 100.00 5.25 100.00 100.00 5.05 100.00 100.00 5.25 100.00 100.00 4.50 100.00 100.00 4.50 100.00 100.00 4.50 100.00 100.00 4.50 100.00 100.00 4.50 100.00 100.00 4.50 100.00 100.00 4.50 100.0 | _ | <u>.</u> | + | 00.9 | 82.20 | 75.85 | 6.50 | 94.70 | 90.05 | 4.95 | 99.90 | 99.60 | 5.05 | 100.00 | 100.00 |
| 15 PSi + PSwii 7.05 100.00 6.25 100.00 100.00 5.30 100.00 4.50 100.00 100.00 4.50 100.00 100.00 PSi + PSwii 7.05 100.00 100.00 6.40 100.00 100.00 5.30 100.00 100.00 4.50 100.00 100.00 PSi + PSwii 7.05 100.00 100.00 6.40 100.00 100.00 5.30 100.00 100.00 4.50 100.00 100.00 PSi + PSwii 7.05 100.00 100.00 6.40 100.00 100.00 5.30 100.00 100.00 4.50 100.00 1 | | | + | 00.9 | 99.85 | 99.85 | 6.50 | 100.00 | 100.00 | 4.95 | 100.00 | 100.00 | 5.05 | 100.00 | 100.00 |
| 1.5 PSi + PSii 7.05 100.00 100.00 6.40 100.00 100.00 5.30 100.00 100.00 4.50 100.00 100.00 PSi + PSii 7.05 100.00 100.00 6.40 100.00 100.00 5.30 100.00 100.00 4.50 100.00 PSi 100.00 PSi 100.00 | | | DG model | 09:9 | 100.00 | 100.00 | 6.25 | 100.00 | 100.00 | 5.25 | 100.00 | 100.00 | 4.80 | 100.00 | 100.00 |
| PSi + IPWii 7.05 100.00 100.00 6.40 100.00 100.00 5.30 100.00 100.00 4.50 100.00 100.00 4.50 100.00 100.00 4.50 100.00 100.00 5.20 100.00 4.50 100.00 5.20 100.00 5.20 100.00 5.20 100.00 5.20 100.00 5.20 100.00 5.20 100.00 5.20 100.00 5.20 5.20 100.00 5.20 | - | т П | PS _I + PS _{II} | 7.05 | 100.00 | 100.00 | 6.40 | 100.00 | 100.00 | 5.30 | 100.00 | 100.00 | 4.50 | 100.00 | 100.00 |
| PS + AlPW 7.05 100.00 100.00 6.40 100.00 100.00 5.30 100.00 100.00 4.50 100.00 PS + PS 93.05 5.40 88.75 98.85 5.50 97.75 100.00 5.70 100.00 5.70 100.00 5.70 PS + PS 93.05 5.40 88.75 98.85 5.50 97.75 100.00 5.70 99.95 100.00 5.70 PS + AlPW 93.05 5.55 89.50 98.85 5.30 97.75 100.00 5.70 99.95 100.00 5.20 PS + AlPW 93.05 5.55 89.50 98.85 5.30 97.75 100.00 5.70 99.95 100.00 5.20 PS + AlPW 100.00 6.40 100.00 100.00 100.00 100.00 4.85 100.00 100.00 5.40 PS + AlPW 100.00 6.55 100.00 100.00 100.00 4.75 100.00 100.00 5.40 PS + AlPW 100.00 6.55 100.00 100.00 100.00 4.45 100.00 100.00 5.40 PS + AlPW 100.00 99.95 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + AlPW 94.60 88.95 99.40 98.70 94.70 100.00 100.00 100.00 100.00 100.00 100.00 PS + AlPW 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + AlPW 100.00 100 | _ | <u>.</u> | $PS_I + IPW_{II}$ | 7.05 | 100.00 | 100.00 | 6.40 | 100.00 | 100.00 | 5.30 | 100.00 | 100.00 | 4.50 | 100.00 | 100.00 |
| DG model 100.00 5.20 100.00 5.50 100.00 5.20 100.00 5.20 100.00 5.20 100.00 5.20 100.00 5.20 100.00 5.20 100.00 5.20 100.00 5.20 100.00 5.20 100.00 5.20 100.00 5.00 6.00 | | | $PS_I + AIPW_{II}$ | 7.05 | 100.00 | 100.00 | 6.40 | 100.00 | 100.00 | 5.30 | 100.00 | 100.00 | 4.50 | 100.00 | 100.00 |
| PSi+PSi 93.05 5.40 88.25 98.85 5.60 97.35 100.00 4.95 99.95 100.00 5.00 PSi+PIWI 93.05 5.40 88.75 98.85 5.50 97.40 100.00 5.70 99.95 100.00 5.00 PSi+AIPWI 93.05 5.40 88.75 98.85 5.50 97.40 100.00 5.70 99.95 100.00 5.00 PSi+AIPWI 93.05 5.55 89.50 100.00 100.00 5.40 100.00 100.00 100.00 100.00 100.00 PSi+AIPWI 100.00 6.40 100.00 100.00 4.65 100.00 100.00 100.00 5.55 100.00 100.00 5.50 100.00 100.00 5.50 100.00 100.00 5.00 100.00 5.00 100.0 | | | DG model | 100.00 | 5.20 | 100.00 | 100.00 | 5.50 | 100.00 | 100.00 | 5.50 | 100.00 | 100.00 | 5.20 | 100.00 |
| PS + IPW 93.05 5.40 88.75 98.85 5.50 97.40 100.00 5.70 99.95 100.00 5.00 PS + AIPW 93.05 5.55 89.50 98.85 5.30 97.75 100.00 5.70 100.00 100.00 4.85 PS + AIPW 93.05 5.55 89.50 98.85 5.30 97.75 100.00 5.00 100.00 100.00 4.85 PS + AIPW 93.05 5.55 89.50 98.85 5.30 97.75 100.00 100.00 100.00 4.85 PS + PS 100.00 6.40 100.00 100.00 100.00 100.00 4.75 100.00 100.00 5.40 PS + PS 100.00 6.55 100.00 100.00 100.00 100.00 4.45 100.00 100.00 5.40 PS + PS 100.00 6.55 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS 100.00 100 | | - | PS _I + PS _{II} | 93.05 | 5.40 | 88.25 | 98.85 | 5.60 | 97.35 | 100.00 | 4.95 | 99.95 | 100.00 | 5.00 | 100.00 |
| PS + AIPW 93.05 5.55 89.50 98.85 5.30 97.75 100.00 5.50 100.00 100.00 4.85 PS + AIPW 93.05 5.55 89.50 98.85 5.30 97.75 100.00 100.00 4.75 100.00 100.00 5.25 PS + PS 100.00 6.40 100.00 100.00 4.35 100.00 100.00 4.45 100.00 100.00 5.40 PS + PS 100.00 6.55 100.00 100.00 4.65 100.00 100.00 4.65 100.00 100.00 5.05 100.00 100.00 5.10 PS + PS 100.00 6.50 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS PS 94.60 86.95 99.40 98.70 96.10 100.00 100.00 100.00 100.00 100.00 PS + PS 94.60 99.95 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS 94.60 99.95 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS PS 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS PS 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS PS 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS PS 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS PS 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS PS 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS + PS 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 PS | 6.0 | _ | $PS_I + IPW_{II}$ | 93.05 | 5.40 | 88.75 | 98.85 | 5.50 | 97.40 | 100.00 | 5.70 | 99.95 | 100.00 | 5.00 | 100.00 |
| DG model 100.00 6.40 100.00 100.00 4.35 100.00 100.00 4.75 100.00 100.00 5.25 100.00 100.00 4.85 100.00 100.00 4.45 100.00 100.00 5.40 100.00 5.40 100.00 100.00 4.45 100.00 100.00 5.40 100.00 100.00 5.51 100.00 100.00 4.65 100.00 100.00 4.65 100.00 100.00 4.65 100.00 100.00 5.05 100.00 100.00 5.05 100.00 100.00 5.05 100.00 | | | $PS_I + AIPW_{II}$ | 93.05 | 5.52 | 89.50 | 98.85 | 5.30 | 97.75 | 100.00 | 5.50 | 100.00 | 100.00 | 4.85 | 100.00 |
| PSI + PSIII 100.00 5.65 100.00 4.35 100.00 100.00 4.45 100.00 100.00 5.40 PSI + IPWII 100.00 6.55 100.00 100.00 4.65 100.00 100.00 4.60 4.60 PSI + AIPWII 100.00 6.60 100.00 100.00 100.00 4.25 100.00 100.00 4.60 PSI + AIPWII 100.00 86.95 99.40 98.70 96.10 100.00 100.00 100.00 100.00 100.00 PSI + PSIII 94.60 86.95 99.40 98.70 96.10 100.00< | | | DG model | 100.00 | 6.40 | 100.00 | 100.00 | 5.40 | 100.00 | 100.00 | 4.75 | 100.00 | 100.00 | 5.25 | 100.00 |
| PS + PW 100.00 6.55 100.00 100.00 4.65 100.00 100.00 4.65 100.00 100.00 4.60 4.65 100.00 4.6 | 9 | - | $PS_I + PS_{II}$ | 100.00 | 5.65 | 100.00 | 100.00 | 4.35 | 100.00 | 100.00 | 4.45 | 100.00 | 100.00 | 5.40 | 100.00 |
| PSi + AlPWii 100.00 6.60 100.00 100.00 100.00 100.00 100.00 100.00 4.25 100.00 100.00 5.10 5.10 5.10 5.10 5.10 | 5 | - | + | 100.00 | 6.55 | 100.00 | 100.00 | 4.65 | 100.00 | 100.00 | 5.05 | 100.00 | 100.00 | 4.60 | 100.00 |
| DG model 100.00 99.95 100.00 1 | | | + | 100.00 | 09.9 | 100.00 | 100.00 | 5.50 | 100.00 | 100.00 | 4.25 | 100.00 | 100.00 | 5.10 | 100.00 |
| 1.2 PS ₁ + PS ₁₁ 94.60 86.95 99.40 98.70 96.10 100.00 10 | | | DG model | 100.00 | 99.95 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| FS + PW 94.60 83.55 99.15 98.70 94.70 100.00 100.00 99.95 100.00 100. | 0 | 0 | PS _I + PS _{II} | 94.60 | 86.95 | 99.40 | 98.70 | 96.10 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| PS ₁ + AIPW ₁₁ 94.60 99.95 100.00 98.70 100.00 10 | 9. | 4 | | 94.60 | 83.55 | 99.15 | 98.70 | 94.70 | 100.00 | 100.00 | 99.95 | 100.00 | 100.00 | 100.00 | 100.00 |
| DG model 100.00 | | | | 94.60 | 99.92 | 100.00 | 98.70 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| 1.5 PS ₁ + PS ₁₁ 100.00 100. | | | DG model | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| -3 PS _I + IPW _{II} 100.00 100 | 9 | <u>۱</u> | $PS_I + PS_{II}$ | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| + AIPW _{II} 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 | 5 | <u>.</u> | $PS_I + IPW_{II}$ | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| | | | + | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |

 Γ_1 denotes the degree of heterogeneity in the continuous exposure effect; Γ_2 denotes the degree of heterogeneity in the binary exposure effect. DG model: Data generation model; PS₁ + PS₁: Using PS regression adjustment in Stage I and II; PS₁ + IPW₁: Using PS regression adjustment in Stage I and AIPW in Stage II.

5.3 Evaluation of homogeneity tests

5.3.1 Methods

To evaluate the homogeneity of the estimated causal effects of a semi-continuous exposure, we conduct a series of simulation studies involving common and different effects across the three outcomes. Specifically, we examine the rejection rates for homogeneity tests of: (1) the continuous exposure effect, (2) the binary exposure effect, and (3) a global test testing homogeneity of both components. These tests are implemented under the conventional covariate regression and the two-stage estimation. To evaluate the characteristics of these tests, we consider various scenarios.

The extent of heterogeneity of the effects is controlled by Γ_1 and Γ_2 with Γ_1 determining the heterogeneity in the continuous exposure effect and Γ_2 controlling the heterogeneity of the binary exposure effect. We let $\Gamma_1=1,0.9,0.6$ to represent no, moderate, and high heterogeneity in the continuous exposure effect; and set $\Gamma_2=1,1.2,1.5$ to represent no, moderate, and high heterogeneity in the binary exposure effect. The simulations are conducted under sample sizes of 350, 500, 1000, and 2000 to assess the performance of the tests across different sample sizes. This design allows for a comprehensive evaluation of the proposed homogeneity tests under four methods.

5.3.2 Results

Table 3 presents the empirical rejection rates of the homogeneity tests for the continuous exposure effect, the binary exposure effect, and the global test across various levels of heterogeneity, sample sizes, and estimation methods when all methods are correctly specified. Under the null scenario with homogeneous exposure effects with $\Gamma_1=1$ and $\Gamma_2=1$, all methods demonstrate reasonably controlled type I error rates. However, for smaller sample sizes of 350 and 500, the rejection rates are inflated and deviate from the nominal 5%. This is possibly due to the relatively large number of parameters being estimated relative to the sample size. As the sample size increases to 1000 and 2000, the rejection rates become closer to 5%, which confirms the validity of the proposed tests in larger samples.

When heterogeneity is introduced in either the continuous exposure effect or the binary exposure effect, all tests show increased power, with rejection rates approaching 100% as both the degree of heterogeneity and the sample size increase. The global test consistently exhibits high power in detecting departures from homogeneity across both components, particularly when Γ_1 and Γ_2 differ from 1. Among all methods, the conventional covariate regression adjustment consistently yields the highest rejection rates under heterogeneity, as it is the most efficient when the data-generating model is correctly specified, particularly in small to moderate samples. The smaller variance of the effect estimates facilitates the detection of differences across outcomes. Among propensity score-based methods, AIPW offers a slight improvement in power for the binary and global tests, and IPW shows greater variability in rejection rates in smaller samples due to its instability. Overall, these results highlight that the proposed homogeneity tests can reliably detect heterogeneity in exposure effects across multiple outcomes.

Overall, the simulation studies demonstrate that the proposed two-stage methods yield unbiased and efficient estimators under correctly specified models, with AIPW in Stage II offering the best balance of robustness and efficiency. Under model misspecification, correct specification of the PS model for the continuous exposure is critical for consistency, while AIPW shows robustness to misspecification of either the PS model for the binary exposure or the imputation models. The homogeneity tests perform well in larger samples and can effectively detect heterogeneity.

6 Prenatal alcohol effects on domains of child cognition

We apply the proposed framework to the Detroit Prenatal Alcohol Exposure (PAE) study to evaluate how maternal drinking during pregnancy influences children's cognition across three domains: Executive Function (EF), Math, and Learning and Memory (LM). This application provides a platform to estimate the causal effects of a semi-continuous PAE and implement a series of tests to assess the homogeneity of effects across outcomes and whether a two-part exposure specification is necessary or whether a single linear causal effect suffices.

6.1 Handling missing data

To address the missing data on confounding variables, we applied multiple imputation to ensure valid inference. In this study, 159 mothers have incomplete data on at least one confounding variable. We generate 20 imputed datasets using multiple imputation by chained equations (MICE) (Van Buuren and Groothuis-Oudshoorn, 2011); see Appendix D for more details. Point estimates are first obtained from each imputed dataset and then aggregated to produce pooled estimates. Standard errors, and variance-covariance matrices are obtained using Rubin's Rules (Rubin, 1976; Little and Rubin, 2019). The pooled variance-covariance matrix derived by Rubin's Rules is used for carrying out the homogeneity tests.

6.2 Estimation strategies

Table 4: Estimated effects of covariates in the two propensity score models

| | | $A \mathbf{Z}_1$ | | $\mathbf{Z}_2, A = 1$ |
|---|----------|------------------|----------|-----------------------|
| | Estimate | Standard error | Estimate | Standard error |
| Intercept | -0.790 | 1.843 | -4.207 | 1.012 |
| Smoking during pregnancy (cigarettes/day) | 0.087 | 0.025 | 0.016 | 0.007 |
| Socioeconomic status at birth | -0.003 | 0.005 | -0.007 | 0.003 |
| Child's gender (female) | -0.597 | 0.315 | -0.168 | 0.165 |
| Mother's age at delivery | 0.052 | 0.035 | 0.058 | 0.018 |
| Prenatal Beck score | 0.020 | 0.022 | 0.027 | 0.011 |
| HOME score at infancy | 0.044 | 0.038 | -0.008 | 0.019 |
| Biological mother's PPVT | -0.003 | 0.014 | -0.007 | 0.007 |
| Biological mother's marital status | -0.096 | 0.485 | -0.046 | 0.275 |
| Prenatal cocaine exposure (days/month) | -0.082 | 0.074 | -0.067 | 0.038 |
| Prenatal marijuana exposure (days/month) | 0.211 | 0.185 | -0.009 | 0.032 |
| Prenatal opiate exposure (days/month) | 0.105 | 0.253 | 0.193 | 0.080 |
| Number of prenatal visits | -0.015 | 0.060 | -0.120 | 0.032 |
| Biological mother's education (year) | -0.035 | 0.115 | 0.095 | 0.059 |
| Parity | -0.446 | 0.214 | -0.003 | 0.095 |
| Gravidity | 0.256 | 0.142 | 0.035 | 0.057 |
| Gestational age at screening | -0.010 | 0.025 | 0.017 | 0.013 |

Our goal is to assess the causal effects of the semi-continuous prenatal alcohol exposure on three outcomes: EF, Math, and LM, by considering both the binary drinking status and the exposure level among drinkers. To achieve this, we apply the conventional covariate regression adjustment and the proposed GEE-based two-stage approach.

Let A_i denote the binary indicator for whether the mother consumed alcohol during pregnancy. Let T_i be the daily amount of alcohol consumed in ounces for individual i. We define $D_i = \log T_i$ to represent the log-transformed daily alcohol consumption, and \mathbf{X}_i as the vector of confounding variables. The outcome vector for individual i is denoted by $\mathbf{Y}_i = (Y_{i1}, Y_{i2}, Y_{i3})'$, where Y_{i1}, Y_{i2} , and Y_{i3} correspond to EF, Math, and LM respectively. The conventional regression model we fit is in the form:

$$E(\mathbf{Y}_i|A_i,D_i,\mathbf{X}_i;\boldsymbol{\theta}) = \boldsymbol{\theta}_0 + \boldsymbol{\theta}_{11}A_i + \boldsymbol{\theta}_{12}A_i(D_i - c) + \mathbf{X}_i'\boldsymbol{\theta}_2,$$

where c is set to -2.31, corresponding to the empirical mean D_i among drinkers. Here, we include all covariates listed in Table 4 in this model.

In addition, we implement a GEE-based two-stage framework to estimate the effects of drinking status and dose of exposure across three outcomes. In the first stage, we fit the multivariate regression model adjusting for the propensity score $S_1(\mathbf{Z}_{i1}; \alpha_1)$:

$$E\{\mathbf{Y}_{i}|D_{i},S_{1}(\mathbf{Z}_{i1};\boldsymbol{\alpha}_{1}),A_{i}=1;\boldsymbol{\gamma}_{1}\}=\boldsymbol{\gamma}_{10}+\boldsymbol{\gamma}_{11}D_{i}+\boldsymbol{\gamma}_{12}S_{1}(\mathbf{Z}_{i1};\boldsymbol{\alpha}_{1}).$$

Then $\hat{\gamma}_{11}$ is incorporated as a vector offset term $\hat{\gamma}_{11}A_i(D_i-c)$ in the second stage to isolate the effect of the binary drinking status A_i . In Stage II, we apply PS regression adjustment, IPW, and AIPW approaches. Table 5 gives all estimated effects of alcohol consumption and drinking status on EF, Math, and LM under all methods. In both PS models, we include all covariates to improve efficiency, following the recommendation of Brookhart et al. (2006) that variables unrelated to the exposure but related to the outcome be retained in the PS model.

6.3 Testing and estimation of common effects

Here, we perform homogeneity tests for alcohol consumption among drinkers and for binary drinking status, along with a global test assessing both components jointly to assess whether domain-specific effects are equal across outcomes under different formulations. Specifically, we test:

- $H_0^{(1)}$: $\gamma_{111} = \gamma_{112} = \gamma_{113}$ to assess the homogeneity of alcohol consumption effects;
- $H_0^{(2)}$: $\gamma_{211} = \gamma_{212} = \gamma_{213}$ to assess the homogeneity of drinking status effects;
- $H_0^{(3)}$: $\gamma_{111} = \gamma_{112} = \gamma_{113}$ and $\gamma_{211} = \gamma_{212} = \gamma_{213}$ to jointly test the homogeneity across both components.

These tests are implemented by Wald statistics based on the estimated coefficients and their variance-covariance matrices across the 20 imputed datasets. Using Rubin's Rule, the test statistic is given by:

$$(\mathbf{R}\bar{\boldsymbol{\beta}} - \mathbf{0})' \{\mathbf{R}\mathbf{V}\mathbf{R}'\}^{-1} (\mathbf{R}\bar{\boldsymbol{\beta}} - \mathbf{0}),$$

where $\bar{\beta}$ is a vector of all pooled estimates, \mathbf{V} is the pooled variance covariance matrix evaluated, and \mathbf{R} is a contrast matrix for the equality constraints. To be more specific, under the homogeneity test for causal dose-response effect, $\bar{\beta} = \bar{\gamma}'_{11}$ with $\bar{\gamma}_{11} = (\bar{\gamma}_{111}, \bar{\gamma}_{112}, \bar{\gamma}_{113})'$, and \mathbf{V} is the corresponding 3×3 pooled covariance matrix. Similarly, for the causal effect of exposure status, $\bar{\beta} = \bar{\gamma}'_{21}$ with $\bar{\gamma}_{21} = (\bar{\gamma}_{211}, \bar{\gamma}_{212}, \bar{\gamma}_{213})'$ and its corresponding pooled covariance matrix \mathbf{V} . The contrast matrix for testing the continuous exposure effect or the binary exposure effect separately is in the form

$$\mathbf{R} = \begin{pmatrix} -1 & 1 & 0 \\ -1 & 0 & 1 \end{pmatrix},$$

For the global test which jointly assesses the homogeneity of both the continuous and binary exposure effects, V is the pooled variance covariance matrix for $\bar{\beta} = (\bar{\gamma}'_{11}, \bar{\gamma}'_{21})'$, and the contrast matrix \mathbf{R}_q is a 4×6 matrix defined as

$$\mathbf{R}_g = egin{pmatrix} \mathbf{R} & \mathbf{0} \ \mathbf{0} & \mathbf{R} \end{pmatrix}.$$

Under the null hypothesis, the Wald statistic W follows a Chi-squared distribution with degrees of freedom equal to the number of constraints: 2 for $H_0^{(1)}$ and $H_0^{(2)}$, and 4 for $H_0^{(3)}$. The resulting p-values are summarized in Table 6.

Since the homogeneity assumption is not rejected, we use inverse-variance weighting to estimate a common effect across the three outcomes to maximize efficiency (Rao et al., 1973; Wei et al., 1989). Let $\hat{\gamma}_{11}$ denote the vector of estimated effects for alcohol consumption, and let $\mathrm{Cov}(\hat{\gamma}_{11})$ denote the corresponding pooled covariance matrix, the submatrix of the full pooled covariance matrix \mathbf{V} corresponding to the indices of $\hat{\gamma}_{11}$. The pooled common effect $\hat{\psi}_1$ is then computed as:

$$\hat{\psi}_1 = \frac{\mathbf{1}' \operatorname{Cov}^{-1}(\hat{\gamma}_{11}) \hat{\gamma}_{11}}{\mathbf{1}' \operatorname{Cov}^{-1}(\hat{\gamma}_{11}) \mathbf{1}},$$

where 1 is a 3-dimensional vector of ones. The same procedure is applied to the drinking status effects to obtain the pooled estimate $\hat{\psi}_2$. The common effects for both exposures under all methods are listed in Table 7.

Table 5: Estimated effects of drinking status and prenatal absolute alcohol consumption per day on cognition domains

| Method | Effect | Domain | Estimate | SE |
|-------------------------------------|--|---------------------|----------|-------|
| | | Executive Function | -1.065 | 0.564 |
| | average logarithm of alcohol consumption per day | Math | -0.655 | 0.568 |
| covariate adjustment | | Learning and Memory | -0.752 | 0.565 |
| covariate adjustifierit | | Executive Function | -0.827 | 2.022 |
| | drinking status | Math | 0.200 | 2.133 |
| | | Learning and Memory | 1.278 | 2.097 |
| | | Executive Function | -0.778 | 0.541 |
| | average logarithm of alcohol consumption per day | Math | -0.328 | 0.579 |
| PS _I +PS _{II} | | Learning and Memory | -0.490 | 0.556 |
| 1 3 +1 3 | | Executive Function | -1.132 | 1.795 |
| | drinking status | Math | -0.116 | 1.927 |
| | | Learning and Memory | 1.396 | 2.069 |
| | | Executive Function | - | - |
| | average logarithm of alcohol consumption per day | Math | - | - |
| PS _I +IPW _{II} | | Learning and Memory | - | - |
| 1 3 +11 44 | | Executive Function | -2.524 | 2.097 |
| | drinking status | Math | -3.878 | 2.417 |
| | | Learning and Memory | 0.442 | 2.491 |
| | | Executive Function | - | - |
| | average logarithm of alcohol consumption per day | Math | - | - |
| PS _I +AIPW _{II} | | Learning and Memory | - | - |
| I OITAII VVII | | Executive Function | -0.781 | 2.067 |
| | drinking status | Math | -0.615 | 1.900 |
| | | Learning and Memory | 1.242 | 2.457 |

 PS_1+PS_{11} : Using PS regression adjustment in Stage I and II; PS_1+IPW_{11} : Using PS regression adjustment in Stage I and IPW in Stage II; PS_1+AIPW_{11} : Using PS regression adjustment in Stage I and AIPW in Stage II.

Table 6: P-values from homogeneity tests for alcohol consumption, drinking status, and global tests

| Method | Alcohol Consumption | Drinking Status | Global |
|-------------------------------------|---------------------|-----------------|--------|
| covariate adjustment | 0.695 | 0.483 | 0.728 |
| PS _I +PS _{II} | 0.668 | 0.362 | 0.602 |
| PS_I+IPW_{II} | - | 0.139 | 0.298 |
| PS _I +AIPW _{II} | - | 0.636 | 0.789 |

PS_{I+}PS_{II}: Using PS regression adjustment in Stage I and II; PS_{I+}IPW_{II}: Using PS regression adjustment in Stage I and IPW in Stage II; PS_{I+}AIPW_{II}: Using PS regression adjustment in Stage I and AIPW in Stage II.

Table 7: Pooled common effects of alcohol consumption and drinking status

| | Alcohol Co | nsumption | Drinking : | Status |
|-------------------------------------|------------|-----------|------------|--------|
| Method | Estimate | SE | Estimate | SE |
| covariate adjustment | -0.841 | 0.439 | 0.422 | 1.728 |
| PS _I +PS _{II} | -0.590 | 0.414 | -0.017 | 1.570 |
| PS_I+IPW_{II} | - | - | -2.471 | 1.937 |
| PS _I +AIPW _{II} | - | - | -0.343 | 1.674 |

 $PS_I + PS_{II}$: Using PS regression adjustment in Stage I and II; $PS_I + IPW_{II}$: Using PS regression adjustment in Stage I and IPW in Stage II; $PS_I + AIPW_{II}$: Using PS regression adjustment in Stage I and AIPW in Stage II.

Table 5 reports the estimated effects of prenatal alcohol exposure on three cognitive domains: EF, Math, LM. Each method evaluates both the effect of log-transformed daily alcohol consumption among drinkers and the binary drinking status. For the effect of drinking amount, all methods yield consistently negative estimates across outcomes, which suggests a potentially adverse effect. Covariate adjustment produces the largest effect sizes, while the two-stage approach yields more moderate estimates with similar standard errors. In contrast, the drinking status effects vary more across methods. IPW in Stage II produces the most extreme estimates with large standard errors, while others yield more moderate results with smaller variability. This variation reflects how each method handles model uncertainty.

Covariate adjustment relies entirely on the outcome model. When correctly specified, this approach is most efficient. However, the relatively large standard error for the drinking status effect suggests potential model misspecification. Propensity score regression only depends on the PS model and avoids the variance inflation introduced by weighting. It provides low variability at the cost of robustness under misspecification. In contrast, IPW also depends on the PS model but reweights the data, which can lead to high variance, especially when extreme weights are present. AIPW improves robustness by integrating both the outcome and PS models. The doubly robust property makes AIPW the most reliable approach among all methods.

Table 6 presents p-values from homogeneity tests. For alcohol consumption, the p-values are approximately 0.70, which provides an evidence of homogeneity. For drinking status, all p-values exceed 0.05. IPW in Stage II yields the lowest p-value, which may be attributed to the instability introduced by the weighting approach. In contrast, AIPW produces the highest p-values for both drinking status and the global test. In summary, the results suggest no significant heterogeneity across outcomes, with AIPW showing the greatest homogeneity.

Based on these findings, Table 7 summarizes the pooled common effects across all outcomes. The estimated common effects of alcohol consumption are negative under all methods, with similar standard errors of approximately 0.4 for both covariate adjustment and the two-stage approaches. For drinking status, PS regression and AIPW in Stage II yield moderate negative estimates with relatively small standard errors, while IPW in Stage II produces the most extreme estimate with the largest standard error. This variance pattern is consistent with the results in Table 5. In contrast, covariate adjustment produces a positive estimate for drinking status, which diverges from the negative estimates obtained via the two-stage methods. This inconsistency may indicate model misspecification in the outcome model and underscores the potential instability of single-model approaches. The two-stage methods, especially AIPW in Stage II, offer a more robust alternative by incorporating both the outcome and propensity score models, leading to more consistent and reliable inference.

7 Discussion

This article introduces a GEE-based two-stage framework for causal inference with semi-continuous exposures and multivariate continuous outcomes. The methodology is motivated by assessing the effects of PAE on three domains of childhood cognition: EF, Math and LM. We formulate a two-stage procedure that estimates the causal effects of both the binary exposure status and the continuous dose among the exposed. Generalized estimating equations

with a working-independence assumption are used in both stages to obtain marginal effect estimates across multiple outcomes. Stage II employs AIPW to achieve doubly robust estimation, yielding consistency if either the propensity score model for the binary exposure or the outcome model is correctly specified, and showing favourable performance under misspecification. We propose homogeneity tests to assess whether the status and dose-response effects are equal across outcomes, and a global homogeneity test that jointly evaluates homogeneity of both components across all outcomes. These tests exhibit appropriate type I error control in large samples. In the Detroit cohort analysis, PAE shows a negative impact on childhood cognition, although insignificant.

However, the proposed framework has several limitations. First, the estimation of the causal dose—response effect in Stage I relies on correct specification of the generalized PS model. Bias in Stage I may propagate to Stage II, which may influence the validity of the final estimates even when AIPW is applied in Stage II. This highlights the need for more flexible or doubly robust methods for continuous exposure in the first stage. A novel kernel smoothing approach proposed by Kennedy et al. (2017) can be applied in the first stage to obtain doubly robust estimation of continuous exposure effects. Second, the working independence assumption in the GEE formulation may lead to efficiency loss when outcomes exhibit substantial within-subject correlation (Liang and Zeger, 1986). Third, although the proposed tests perform well in larger samples, simulation results show inflated type I error rates under the null hypothesis in smaller samples. This is possibly due to the relatively high dimensionality of the parameter space. To address this, small-sample corrections or penalized Wald statistics may be considered to improve the finite-sample performance of the tests (Li and Redden, 2015).

References

- Donald B. Rubin. Estimating causal effects of treatments in randomized and nonrandomized studies. *Journal of Educational Psychology*, 66(5):688–701, 1974.
- Paul R Rosenbaum and Donald B Rubin. The central role of the propensity score in observational studies for causal effects. *Biometrika*, 70(1):41–55, 1983.
- Paul R Rosenbaum and Donald B Rubin. Reducing bias in observational studies using subclassification on the propensity score. *Journal of the American Statistical Association*, 79(387):516–524, 1984.
- Keisuke Hirano and Guido W Imbens. The propensity score with continuous treatments. *Applied Bayesian Modeling and Causal Inference from Incomplete-data Perspectives*, 226164:73–84, 2004.
- Kosuke Imai and David A Van Dyk. Causal inference with general treatment regimes: generalizing the propensity score. *Journal of the American Statistical Association*, 99(467):854–866, 2004.
- Tugba Akkaya-Hocagil, Richard J Cook, Sandra W Jacobson, Joseph L Jacobson, and Louise M Ryan. Propensity score analysis for a semi-continuous exposure variable: a study of gestational alcohol exposure and childhood cognition. *Journal of the Royal Statistical Society Series A: Statistics in Society*, 184(4):1390–1413, 2021.
- Kecheng Li, Tugba Akkaya-Hocagil, Richard J Cook, Louise M Ryan, R Colin Carter, Khue-Dung Dang, Joseph L Jacobson, and Sandra W Jacobson. Use of generalized propensity scores for assessing effects of multiple exposures. *Statistics in Biosciences*, pages 1–30, 2023.
- Xiaoya Wang, Richard J Cook, Yeying Zhu, Tugba Akkaya-Hocagil, R Colin Carter, Sandra W Jacobson, Joseph L Jacobson, and Louise M Ryan. Two-stage estimation for causal inference involving a semi-continuous exposure. *arXiv preprint arXiv:2511.20985*, 2025.
- Joseph L Jacobson, Tugba Akkaya-Hocagil, Louise M Ryan, Neil C Dodge, Gale A Richardson, Heather Carmichael Olson, Claire D Coles, Nancy L Day, Richard J Cook, and Sandra W Jacobson. Effects of prenatal alcohol exposure on cognitive and behavioral development: Findings from a hierarchical meta-analysis of data from six prospective longitudinal us cohorts. *Alcoholism: Clinical and Experimental Research*, 45(10):2040–2058, 2021.
- Mary Sammel, Xihong Lin, and Louise Ryan. Multivariate linear mixed models for multiple outcomes. *Statistics in Medicine*, 18(17-18):2479–2492, 1999.
- Xihong Lin, Louise Ryan, Mary Sammel, Daowen Zhang, Chantana Padungtod, and Xiping Xu. A scaled linear mixed model for multiple outcomes. *Biometrics*, 56(2):593–601, 2000.
- Jason Roy, Xihong Lin, and Louise M Ryan. Scaled marginal models for multiple continuous outcomes. *Biostatistics*, 4(3):371–383, 2003.
- Sally W Thurston, David Ruppert, and Philip W Davidson. Bayesian models for multiple outcomes nested in domains. *Biometrics*, 65(4):1078–1086, 2009.
- Edward H Kennedy, Shreya Kangovi, and Nandita Mitra. Estimating scaled treatment effects with multiple outcomes. *Statistical methods in medical research*, 28(4):1094–1104, 2019.

- Monia Lupparelli and Alessandra Mattei. Joint and marginal causal effects for binary non-independent outcomes. *Journal of Multivariate Analysis*, 178:104609, 2020.
- Jin-Hong Du, Zhenghao Zeng, Edward H Kennedy, Larry Wasserman, and Kathryn Roeder. Causal inference for genomic data with multiple heterogeneous outcomes. *Journal of the American Statistical Association*, (just-accepted): 1–24, 2025.
- Sandra W Jacobson, Lisa M Chiodo, Robert J Sokol, and Joseph L Jacobson. Validity of maternal report of prenatal alcohol, cocaine, and smoking in relation to neurobehavioral outcome. *Pediatrics*, 109(5):815–825, 2002.
- Sandra W Jacobson, Joseph L Jacobson, Robert J Sokol, Lisa M Chiodo, and Raluca Corobana. Maternal age, alcohol abuse history, and quality of parenting as moderators of the effects of prenatal alcohol exposure on 7.5-year intellectual function. *Alcoholism: Clinical and Experimental Research*, 28(11):1732–1745, 2004.
- Khue-Dung Dang, Louise M Ryan, Tugba Akkaya-Hocagil, Richard J Cook, Gale A Richardson, Nancy L Day, Claire D Coles, Heather Carmichael Olson, Sandra W Jacobson, and Joseph L Jacobson. Bayesian modelling of effects of prenatal alcohol exposure on child cognition based on data from multiple cohorts. *Australian & New Zealand Journal of Statistics*, 65(3):167–186, 2023.
- Valerie A Smith, Brian Neelon, Matthew L Maciejewski, and John S Preisser. Two parts are better than one: modeling marginal means of semicontinuous data. *Health Services and Outcomes Research Methodology*, 17:198–218, 2017.
- Jersey Neyman. Sur les applications de la théorie des probabilités aux experiences agricoles: Essai des principes. *Roczniki Nauk Rolniczych*, 10(1):1–51, 1923.
- Donald B Rubin. Randomization analysis of experimental data: the fisher randomization test comment. *Journal of the American Statistical Association*, 75(371):591–593, 1980.
- Donald B Rubin. Comment: Neyman (1923) and causal inference in experiments and observational studies. *Statistical Science*, 5(4):472–480, 1990.
- Stephen R Cole and Miguel A Hernán. Constructing inverse probability weights for marginal structural models. *American Journal of Epidemiology*, 168(6):656–664, 2008.
- Kung-Yee Liang and Scott L Zeger. Longitudinal data analysis using generalized linear models. *Biometrika*, 73(1): 13–22, 1986.
- Scott L Zeger and Kung-Yee Liang. Longitudinal data analysis for discrete and continuous outcomes. *Biometrics*, pages 121–130, 1986.
- Aad W Van der Vaart. Asymptotic statistics, volume 3. Cambridge university press, 2000.
- Joseph L Doob. The limiting distributions of certain statistics. *The Annals of Mathematical Statistics*, 6(3):160–169, 1935.
- Stef Van Buuren and Karin Groothuis-Oudshoorn. mice: Multivariate imputation by chained equations in r. *Journal of statistical software*, 45:1–67, 2011.
- Donald B Rubin. Inference and missing data. *Biometrika*, 63(3):581–592, 1976.
- Roderick JA Little and Donald B Rubin. Statistical analysis with missing data, volume 793. John Wiley & Sons, 2019.
- M Alan Brookhart, Sebastian Schneeweiss, Kenneth J Rothman, Robert J Glynn, Jerry Avorn, and Til Stürmer. Variable selection for propensity score models. *American Journal of Epidemiology*, 163(12):1149–1156, 2006.
- Calyampudi Radhakrishna Rao, Calyampudi Radhakrishna Rao, Mathematischer Statistiker, Calyampudi Radhakrishna Rao, and Calyampudi Radhakrishna Rao. *Linear statistical inference and its applications*, volume 2. Wiley New York, 1973.
- Lee-Jen Wei, Danyu Y Lin, and Lisa Weissfeld. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. *Journal of the American Statistical Association*, 84(408):1065–1073, 1989.
- Edward H Kennedy, Zongming Ma, Matthew D McHugh, and Dylan S Small. Non-parametric methods for doubly robust estimation of continuous treatment effects. *Journal of the Royal Statistical Society Series B: Statistical Methodology*, 79(4):1229–1245, 2017.
- Peng Li and David T Redden. Small sample performance of bias-corrected sandwich estimators for cluster-randomized trials with binary outcomes. *Statistics in Medicine*, 34(2):281–296, 2015.
- Ian R White, Patrick Royston, and Angela M Wood. Multiple imputation using chained equations: issues and guidance for practice. *Statistics in medicine*, 30(4):377–399, 2011.

A Identifying Assumptions

These are the four assumptions in our specific setting with a semi-continuous exposure and multiple outcomes:

Assumption 1 (Stable Unit Treatment Value Assumption) The potential outcome for one individual are independent of the exposure of another individual.

Assumption 2 (Consistency) $\mathbf{Y}_i = \mathbf{Y}_i(1,d)$ if the *i*-th subject is exposed with dose $D_i = d$ for any positive d, and $\mathbf{Y}_i = \mathbf{Y}_i(0,0)$ if unexposed. It assumes that the potential outcomes of an individual under their observed exposure is exactly the outcome that was observed.

Assumption 3 (Ignorability) The potential outcome is independent of the observed exposure given covariates, i.e., $\mathbf{Y}_i(a,d) \perp A_i, D_i \mid \mathbf{X}_i = \mathbf{x}$. More specifically, $\mathbf{Y}_i(1,d) \perp D_i \mid A_i = 1, \mathbf{X}_i = \mathbf{x}$ and $\mathbf{Y}_i(1,c), \mathbf{Y}_i(0,0) \perp A_i \mid \mathbf{X}_i$ where c is a pre-specified constant representing the reference dose.

Assumption 4 (Positivity) The conditional density $f(D_i = d \mid A_i = 1, \mathbf{X}_i) > 0$ for all d among the exposed, and $\Pr(A_i = a \mid \mathbf{X}_i) > 0$ for a = 0, 1. This implies that any individual in the exposed group (A = 1) has a positive probability of receiving a dose and receiving either exposure status conditional on covariates; and every individual has a positive probability of being either exposed or unexposed.

B Analysis Stage II: Effect of the Binary Exposure

In Stage II, the causal effect of the binary exposure can be estimated using propensity score regression adjustment, inverse probability weighting (IPW), or augmented inverse probability weighting (AIPW). Here we outline the first two approaches to illustrate their implementation.

B.1 Propensity score (PS) regression adjustment

Here we fit a multivariate model with the exposure indicator A, a propensity score covariate, and an offset term. This model is specified as

$$E\left\{\begin{pmatrix} Y_{i1} \\ Y_{i2} \\ \vdots \\ Y_{iJ} \end{pmatrix} \middle| D_i, A_i, S_2(\mathbf{Z}_{i2}; \boldsymbol{\alpha}_2) \right\} = \begin{pmatrix} \gamma_{201} \\ \gamma_{202} \\ \vdots \\ \gamma_{20J} \end{pmatrix} + \begin{pmatrix} \gamma_{211} \\ \gamma_{212} \\ \vdots \\ \gamma_{21J} \end{pmatrix} A_i + \begin{pmatrix} \gamma_{221} \\ \gamma_{222} \\ \vdots \\ \gamma_{22J} \end{pmatrix} S_2(\mathbf{Z}_{i2}; \boldsymbol{\alpha}_2) + \text{offset} \left\{ \begin{pmatrix} \gamma_{111} \\ \gamma_{112} \\ \vdots \\ \gamma_{11J} \end{pmatrix} A_i(D_i - c) \right\},$$

$$(12)$$

where $S_2(\mathbf{Z}_{i2}; \boldsymbol{\alpha}_2)$ is the estimated propensity score for the binary exposure. We let $\boldsymbol{\gamma}_{20} = (\gamma_{201}, \dots, \gamma_{20J})'$, $\boldsymbol{\gamma}_{21} = (\gamma_{211}, \dots, \gamma_{21J})'$ denote the causal parameters of interest, and $\boldsymbol{\gamma}_{22} = (\gamma_{221}, \dots, \gamma_{22J})'$ be the vector of coefficients for the propensity scores. We denote the full set of parameters in (12) by $\boldsymbol{\gamma}_2 = (\boldsymbol{\gamma}_{20}', \boldsymbol{\gamma}_{21}', \boldsymbol{\gamma}_{22}')'$; we let $\boldsymbol{\phi}_2 = (\boldsymbol{\gamma}_2', \boldsymbol{\alpha}_2')'$. A GEE for estimating $\boldsymbol{\gamma}_2$ is in the form

$$\tilde{\mathbf{U}}_{21}(\mathcal{D}; \gamma_1, \phi_2) = \sum_{i=1}^n \tilde{\mathbf{U}}_{i21}(\mathcal{D}_i; \gamma_1, \phi_2) = \mathbf{0}$$
 (13)

where

$$\tilde{\mathbf{U}}_{i21}(\mathcal{D}_i;\boldsymbol{\gamma}_1,\boldsymbol{\phi}_2) = \frac{\partial \boldsymbol{\mu}_{i21}(\boldsymbol{\phi}_2)}{\partial \boldsymbol{\gamma}_2} \mathbf{I} \big[\mathbf{Y}_i - [\boldsymbol{\mu}_{i21}(\boldsymbol{\phi}_2) + \text{offset} \left\{ \boldsymbol{\gamma}_{11} A_i (D_i - c) \right\}] \big],$$

with $\mu_{i21}(\phi_2) = \gamma_{20} + \gamma_{21}A_i + \gamma_{22}S_2(\mathbf{Z}_2; \boldsymbol{\alpha}_2)$ under a working independence assumption. The parameter $\boldsymbol{\alpha}_2$ can be estimated by solving

$$\mathbf{U}_{22}(\mathcal{D}; \boldsymbol{\alpha}_2) = \sum_{i=1}^{n} \mathbf{U}_{i22}(\mathcal{D}_i; \boldsymbol{\alpha}_2) = \mathbf{0}$$
(14)

where

$$\mathbf{U}_{i22}\left(\mathcal{D}_{i};\boldsymbol{\alpha}_{2}\right) = \frac{\partial S_{2}(\mathbf{Z}_{i2};\boldsymbol{\alpha}_{2})}{\partial \boldsymbol{\alpha}_{2}} \frac{1}{S_{2}\left(\mathbf{Z}_{i2};\boldsymbol{\alpha}_{2}\right)\left\{1 - S_{2}\left(\mathbf{Z}_{i2};\boldsymbol{\alpha}_{2}\right)\right\}} \left\{A - S_{2}(\mathbf{Z}_{i2};\boldsymbol{\alpha}_{2})\right\}.$$

Then the joint Stage II estimating equation under PS regression adjustment is

$$\tilde{\mathbf{U}}_2(\mathcal{D}; \boldsymbol{\gamma}_1, \boldsymbol{\phi}_2) = \sum_{i=1}^n \tilde{\mathbf{U}}_{i2}(\mathcal{D}_i; \boldsymbol{\gamma}_1, \boldsymbol{\phi}_2) = \mathbf{0}$$
(15)

where $\tilde{\mathbf{U}}_{i2}\left(\mathcal{D}_{i};\boldsymbol{\gamma}_{1},\boldsymbol{\phi}_{2}\right)=\left\{\tilde{\mathbf{U}}_{i21}'\left(\mathcal{D}_{i};\boldsymbol{\gamma}_{1},\boldsymbol{\phi}_{2}\right),\mathbf{U}_{i22}'\left(\mathcal{D}_{i};\boldsymbol{\alpha}_{2}\right)\right\}'$. By combining Stage I estimating equation and (15), we obtain the joint estimating equation for the two-stage analysis under PS regression adjustment in both stages:

$$\tilde{\mathbf{U}}(\mathcal{D}; \mathbf{\Omega}) = \left\{ \begin{array}{c} \mathbf{U}_{1}(\mathcal{D}; \boldsymbol{\phi}_{1}) \\ \tilde{\mathbf{U}}_{2}(\mathcal{D}; \boldsymbol{\gamma}_{1}, \boldsymbol{\phi}_{2}) \end{array} \right\} = \mathbf{0}$$
(16)

where $\Omega = (\phi_1', \phi_2')'$. In Stage II, γ_{21} corresponds to the causal effect of exposure at the reference dose compared to no exposure.

B.2 Inverse probability weighting (IPW)

Here we use the propensity score $S_2(\mathbf{Z}_{i2}; \boldsymbol{\alpha}_2)$ to specify weights for fitting a multivariate marginal structural model in the second stage. Specifically we consider

$$E\left\{ \begin{pmatrix} Y_{i1} \\ Y_{i2} \\ \vdots \\ Y_{iJ} \end{pmatrix} \middle| A_i, D_i \right\} = \begin{pmatrix} \gamma_{201} \\ \gamma_{202} \\ \vdots \\ \gamma_{20J} \end{pmatrix} + \begin{pmatrix} \gamma_{211} \\ \gamma_{212} \\ \vdots \\ \gamma_{21J} \end{pmatrix} A_i + \text{offset} \left\{ \begin{pmatrix} \gamma_{111} \\ \gamma_{112} \\ \vdots \\ \gamma_{11J} \end{pmatrix} A_i (D_i - c) \right\}, \tag{17}$$

where $\gamma_{20}=(\gamma_{201},...,\gamma_{20J})',$ $\gamma_{21}=(\gamma_{211},...,\gamma_{21J})'$ and $\gamma_2=(\gamma_{20}',\gamma_{21}')'$. An inverse probability weighted GEE to estimate γ_1 is

$$\bar{\mathbf{U}}_{21}(\mathcal{D}; \gamma_1, \phi_2) = \sum_{i=1}^n \bar{\mathbf{U}}_{i21}(\mathcal{D}_i; \gamma_1, \phi_2) = \mathbf{0}$$
(18)

where

$$\bar{\mathbf{U}}_{i21}(\mathcal{D}_{i};\boldsymbol{\gamma}_{1},\boldsymbol{\phi}_{2}) = \sum_{a=0}^{1} w_{i}\left(a;\boldsymbol{\alpha}_{2}\right) \frac{\partial \boldsymbol{\mu}_{21}\left(a;\boldsymbol{\gamma}_{2}\right)}{\partial \boldsymbol{\gamma}_{2}} \mathbf{I}\left[\mathbf{Y}_{i} - \left[\boldsymbol{\mu}_{21}\left(a;\boldsymbol{\gamma}_{2}\right) + \text{offset}\left\{\boldsymbol{\gamma}_{11}a(D_{i} - c)\right\}\right]\right]$$

under working independence assumption with

$$w_i(a; \boldsymbol{\alpha}_2) = \frac{I(A_i = a)}{S_2(\mathbf{Z}_{i2}; \boldsymbol{\alpha}_2)^a \left\{1 - S_2(\mathbf{Z}_{i2}; \boldsymbol{\alpha}_2)\right\}^{1-a}}$$
(19)

and

$$\mu_{21}(a;\gamma_2) = \gamma_{20} + \gamma_{21}a. \tag{20}$$

for a=0,1. The bar in (18) indicates that this estimating function is under the IPW approach in Stage II. The Stage II estimating equation under IPW is

$$\bar{\mathbf{U}}_2(\mathcal{D}; \boldsymbol{\gamma}_1, \boldsymbol{\phi}_2) = \sum_{i=1}^n \bar{\mathbf{U}}_{i2}(\mathcal{D}_i; \boldsymbol{\gamma}_1, \boldsymbol{\phi}_2) = \mathbf{0}$$
(21)

where $\bar{\mathbf{U}}_{i2}(\mathcal{D}_i; \boldsymbol{\gamma}_1, \boldsymbol{\phi}_2) = \left\{\bar{\mathbf{U}}'_{i21}(\mathcal{D}_i; \boldsymbol{\gamma}_1, \boldsymbol{\phi}_2), \mathbf{U}'_{i22}(\mathcal{D}_i; \boldsymbol{\alpha}_2)\right\}'$. Taking Stage I estimating equation and (21) together, the joint estimating equation for the two-stage analysis applying IPW in Stage II is

$$\bar{\mathbf{U}}(\mathcal{D}; \mathbf{\Omega}) = \left\{ \begin{array}{c} \mathbf{U}_1(\mathcal{D}; \boldsymbol{\phi}_1) \\ \bar{\mathbf{U}}_2(\mathcal{D}; \boldsymbol{\gamma}_1, \boldsymbol{\phi}_2) \end{array} \right\} = \mathbf{0}. \tag{22}$$

C Proof of Asymptotic Properties

Theorem 2 Suppose assumptions listed in Section 2.1 hold and the Stage I PS regression model $S_1(\mathbf{Z}_1; \boldsymbol{\alpha}_1)$ is correctly specified. Then the solution $\hat{\boldsymbol{\phi}}_1 = (\hat{\gamma}_1', \hat{\boldsymbol{\alpha}}_1')'$ to (7) is consistent for $\boldsymbol{\phi}_1$. In particular, $\hat{\gamma}_{11}$ is a consistent estimator of $\boldsymbol{\theta}_{11}$, the causal dose–response effect of the continuous exposure in (1).

Theorem 3 Suppose assumptions listed in Section 2.1 hold and $\hat{\gamma}_1$ consistently estimates θ_{11} , then the solution $\hat{\phi}_2$ to (12) is consistent for ϕ_2 when at least one of the Stage II propensity score model $S_2(\mathbf{Z}_2; \alpha_2)$ and the imputation model $\mathbf{m}_a(\theta)$ are correctly specified. In particular, $\hat{\gamma}_{21}$ consistently estimates θ_2 , the causal effect of exposure at the reference dose versus no exposure in (1).

C.1 Proof of Theorem 2

Assume Assumptions 1 to 4 hold, and the Stage I propensity score $S_1(\mathbf{Z}_1; \boldsymbol{\alpha}_1)$ is correctly specified. Here, we aim to show

$$E_{\mathbf{Y}_i,D_i,A_i,\mathbf{X}_i} \{ U_{i11}(\mathcal{D}_i | \phi_1) \} = \mathbf{0}$$

$$(23)$$

Firstly, we rewrite this estimating function as

$$\boldsymbol{U}_{i11}(\mathcal{D}_{i}|\boldsymbol{\phi}_{1}) = A_{i} \frac{\partial \boldsymbol{\mu}_{i11}(\boldsymbol{\phi}_{1})}{\partial \boldsymbol{\gamma}_{1}} \mathbf{I} \left\{ \mathbf{Y}_{i} - \boldsymbol{\mu}_{i11}(\boldsymbol{\phi}_{1}) \right\}, \tag{24}$$

$$= \begin{cases} A_{i} \frac{\partial \mu_{i111} \left(\phi_{1}^{(1)}\right)}{\partial \gamma_{1}^{(1)}} \left\{ Y_{i1} - \mu_{i111} \left(\phi_{1}^{(1)}\right) \right\} \\ A_{i} \frac{\partial \mu_{i112} \left(\phi_{1}^{(2)}\right)}{\partial \gamma_{1}^{(2)}} \left\{ Y_{i2} - \mu_{i112} \left(\phi_{1}^{(2)}\right) \right\} \\ \vdots \\ A_{i} \frac{\partial \mu_{i11J} \left(\phi_{1}^{(J)}\right)}{\partial \gamma_{1}^{(J)}} \left\{ Y_{iJ} - \mu_{i11J} \left(\phi_{1}^{(J)}\right) \right\} \end{cases}$$

$$(25)$$

$$= \begin{cases} \mathbf{U}_{i111}(\mathcal{D}_{i1}; \boldsymbol{\phi}_{1}^{(1)}) \\ \mathbf{U}_{i112}(\mathcal{D}_{i2}; \boldsymbol{\phi}_{1}^{(2)}) \\ \vdots \\ \mathbf{U}_{i11J}(\mathcal{D}_{iJ}; \boldsymbol{\phi}_{1}^{(J)}) \end{cases}$$
(26)

where
$$\boldsymbol{\gamma}_{1}^{(j)}=(\gamma_{10j},\gamma_{11j},\gamma_{12j})',\; \boldsymbol{\phi}_{1}^{(j)}=(\boldsymbol{\gamma}_{1}^{\prime(j)},\boldsymbol{\alpha}_{1})',\; \mu_{i11j}\left(\boldsymbol{\phi}_{1}^{(j)}\right)=\gamma_{10j}+\gamma_{11j}D_{i}+\gamma_{12j}S_{1}(\mathbf{Z}_{i1};\boldsymbol{\alpha}_{1})\; \text{for}\; j=1,2,\ldots,n$$

1, ..., J, and $\mathbf{U}_{i11j}(\mathcal{D}_{ij}; \boldsymbol{\phi}_1^{(j)})$ denotes the estimating function for the j-th outcome with $D_{ij} = (Y_{ij}, \mathbf{X}_i, A_i, D_i)$. The step from (24) to (25) is an algebraic expansion. The step from (25) to (26) simply introduces notation for the estimating function U_{i11j} .

Therefore, showing that (23) holds is equivalent to showing that

$$E_{\mathbf{Y}_{ij},D_{i},A_{i},\mathbf{X}_{i}}\left\{U_{i11j}(\mathcal{D}_{i}|\phi_{1}^{(j)})\right\} = \mathbf{0}.$$
(27)

Wang et al. (2025) demonstrate that (27) holds in the single-outcome setting, showing that the estimating equation is unbiased when the Stage I propensity score is correctly specified. In our multivariate GEE framework, $U_{i11}(\mathcal{D}_i|\phi_1)$ in (26) is a direct stack of the J outcome-specific estimating equations. Under the working independence assumption, each component U_{i11j} contributes independently to the joint estimating equation. Hence,

$$E\{U_{i11}(\mathcal{D}_i|\phi_1)\} = (E\{U_{i111}\}, E\{U_{i112}\}, \dots, E\{U_{i11J}\})' = \mathbf{0},$$

since each $E\{U_{i11j}\}$ vanishes by the result of Wang et al. Wang et al. (2025). Thus, the unbiasedness property in (23) follows immediately under the working independence assumption, extending the single-outcome proof to the multivariate case.

C.2 Proof of Theorem 3

Assume Assumptions 1 to 4 hold, and $\hat{\gamma}_{11}$ obtained from Stage I is consistent to θ_1 . Here, we aim to show the AIPW estimating function is an unbiased estimating function to prove consistency when at least one of the propensity score model $S_2(\mathbf{Z}_2; \alpha_2)$ and the imputation model $\mathbf{m}_a(\theta)$ are correctly specified.

To prove consistency, we can show

$$E_{\mathbf{Y}_{i},D_{i},A_{i},\mathbf{X}_{i}}\left\{\mathbf{U}_{i21}(\mathcal{D}_{i};\boldsymbol{\gamma}_{1},\boldsymbol{\phi}_{2})\right\}=\mathbf{0}.$$
(28)

We first rewrite the estimating function as

$$\mathbf{U}_{i21}(\mathcal{D}_{i}; \boldsymbol{\gamma}_{1}, \boldsymbol{\phi}_{2}) = \begin{cases} \mathbf{U}_{i211}(\mathcal{D}_{i1}; \boldsymbol{\gamma}_{111}, \boldsymbol{\phi}_{2}^{(1)}) \\ \mathbf{U}_{i212}(\mathcal{D}_{i2}; \boldsymbol{\gamma}_{112}, \boldsymbol{\phi}_{2}^{(2)}) \\ \vdots \\ \mathbf{U}_{i21J}(\mathcal{D}_{iJ}; \boldsymbol{\gamma}_{11J}, \boldsymbol{\phi}_{2}^{(J)}) \end{cases}$$
(29)

where $\mathbf{U}_{i21j}(\mathcal{D}_{i1}; \gamma_{11j}, \boldsymbol{\phi}_2^{(j)})$ is defined as

$$\sum_{a=0}^{1} w_{i}(a; \boldsymbol{\alpha}_{2}) \frac{\partial \mu_{21j}(a; \boldsymbol{\gamma}_{2}^{(j)})}{\partial \boldsymbol{\gamma}_{2}^{(j)}} \left[Y_{ij} - \left[\mu_{21j}(a; \boldsymbol{\gamma}_{2}^{(j)}) + \text{offset} \{ \gamma_{11j} A_{i}(D_{i} - c) \} \right] \right] - \{ w_{i}(a; \boldsymbol{\alpha}_{2}) - 1 \} \boldsymbol{g}_{ij}(a; \boldsymbol{\zeta}^{(j)}, \boldsymbol{\gamma}_{2}^{(j)})$$

where $\mu_{21j}(a; \boldsymbol{\gamma}_2^{(j)}) = \gamma_{20j} + \gamma_{21j}a$ with $\boldsymbol{\gamma}_2^{(r)} = (\gamma_{20j}, \gamma_{21j})', \boldsymbol{\phi}_2^{\prime(j)} = (\boldsymbol{\gamma}_2^{(j)'}, \boldsymbol{\alpha}_2', \boldsymbol{\zeta}^{(j)'})';$

$$\boldsymbol{g}_{ij}\left(\boldsymbol{a};\boldsymbol{\zeta}^{(j)},\boldsymbol{\gamma_2}^{(j)}\right) = \frac{\partial \mu_{21j}\left(\boldsymbol{a};\boldsymbol{\gamma}_2^{(j)}\right)}{\partial \boldsymbol{\gamma}_2^{(j)}} \left\{ m_{iaj}(\boldsymbol{\zeta}^{(j)}) - \mu_{21j}\left(\boldsymbol{a};\boldsymbol{\gamma}_2^{(j)}\right) \right\}$$

where $m_{iaj}(\zeta^{(j)}) = \zeta_{a0j} + \zeta'_{a1j}\mathbf{X}_{i1} + \zeta'_{a2j}\mathbf{X}_{i2} + \zeta'_{a3j}\mathbf{X}_{i3}$ with $\zeta^{(j)} = (\zeta_1^{(j)'}, \zeta_0^{(j)'})'$ with $\zeta_a^{(j)} = (\zeta_{a0j}, \zeta'_{a1j}, \zeta'_{a2j}, \zeta'_{a3j})'$ for a = 0, 1.

Wang et al. (2025) show, in the single-outcome setting, the AIPW estimating function is unbiased if either the propensity score model or the imputation model is correctly specified, provided the Stage I quantity entering the offset is consistently estimated. Applying this result to each outcome j yields

$$E\left\{\mathbf{U}_{i21j}(\mathcal{D}_{ij};\gamma_{11j},\boldsymbol{\phi}_{2}^{(j)})\right\} = \mathbf{0}, \quad j = 1,\ldots,J.$$

Therefore, by (29) and taking expectations componentwise,

$$E\{\mathbf{U}_{i21}(\mathcal{D}_i; \boldsymbol{\gamma}_1, \boldsymbol{\phi}_2)\} = \{E(\mathbf{U}_{i211}), \dots, E(\mathbf{U}_{i21J})\}' = \mathbf{0}.$$

Therefore, Theorem 2 holds.

C.3 Proof of Theorem 1

Here we derive the asymptotic covariance matrix of the estimator obtained from two-stage analysis focusing on applying PS regression adjustment in stage I and use of AIPW in stage II. Recall that $\hat{\Omega}=(\hat{\phi}_1',\hat{\phi}_2')'$ is the solution of

$$\hat{\mathbf{U}}(\mathbf{\Omega}) = \left\{ egin{array}{l} \mathbf{U}_1\left(\mathcal{D}; oldsymbol{\phi}_1
ight) \ \hat{\mathbf{U}}_2\left(\mathcal{D}; oldsymbol{\gamma}_1, oldsymbol{\phi}_2
ight) \end{array}
ight\} = \mathbf{0}.$$

where $\phi_1=(\pmb{\gamma}_1',\pmb{\alpha}_1')'$ and $\phi_2=(\pmb{\gamma}_2',\pmb{\alpha}_2')'.$

Since

$$\hat{\mathbf{U}}(\hat{\mathbf{\Omega}}) = \hat{\mathbf{U}}(\mathbf{\Omega}) + rac{\partial \hat{\mathbf{U}}(\mathbf{\Omega})}{\partial \mathbf{\Omega}'} \left(\hat{\mathbf{\Omega}} - \mathbf{\Omega}
ight) + o_p \left(rac{1}{\sqrt{n}}
ight)$$

then we have

$$\sqrt{n}(\hat{\boldsymbol{\Omega}} - \boldsymbol{\Omega}) = \left\{ -\frac{1}{n} \frac{\partial \hat{\mathbf{U}}(\boldsymbol{\Omega})}{\partial \boldsymbol{\Omega}'} \right\}^{-1} \left\{ \frac{1}{\sqrt{n}} \hat{\mathbf{U}}(\boldsymbol{\Omega}) \right\} + o_p(1)$$

where $\frac{\partial \hat{\mathbf{U}}(\mathbf{\Omega})}{\partial \mathbf{\Omega}'}$ is

As $n \to \infty$, \mathcal{A} converges to

$$E\left\{-\frac{\partial \hat{\mathbf{U}}_{i}(\mathbf{\Omega})}{\partial \mathbf{\Omega}'}\right\} = \begin{cases} \mathcal{A}_{11} & \mathcal{A}_{12} & \mathbf{0} & \mathbf{0} & \mathbf{0} & \mathbf{0} \\ \mathbf{0} & \mathcal{A}_{22} & \mathbf{0} & \mathbf{0} & \mathbf{0} & \mathbf{0} \\ \mathcal{A}_{31} & \mathbf{0} & \mathcal{A}_{33} & \mathcal{A}_{34} & \mathcal{A}_{35} & \mathcal{A}_{36} \\ \mathbf{0} & \mathbf{0} & \mathbf{0} & \mathcal{A}_{44} & \mathbf{0} & \mathbf{0} \\ \mathcal{A}_{51} & \mathbf{0} & \mathbf{0} & \mathbf{0} & \mathcal{A}_{55} & \mathbf{0} \\ \mathbf{0} & \mathbf{0} & \mathbf{0} & \mathbf{0} & \mathbf{0} & \mathcal{A}_{66} \end{cases}$$

where

$$\mathcal{A}_{11} = E\left\{-\frac{\partial \mathbf{U}_{i11}(\mathcal{D}_{i}; \boldsymbol{\phi}_{1})}{\partial \boldsymbol{\gamma}_{1}}\right\}, \mathcal{A}_{12} = E\left\{-\frac{\partial \mathbf{U}_{i11}(\mathcal{D}_{i}; \boldsymbol{\phi}_{1})}{\partial \boldsymbol{\alpha}_{2}}\right\},$$

$$\mathcal{A}_{22} = E\left\{-\frac{\partial \mathbf{U}_{i12}(\boldsymbol{\alpha}_{2})}{\partial \boldsymbol{\alpha}_{2}}\right\}, \mathcal{A}_{31} = E\left\{\frac{\partial \hat{\mathbf{U}}_{i21}(\mathcal{D}_{i}; \boldsymbol{\gamma}_{1}, \boldsymbol{\phi}_{2})}{\partial \boldsymbol{\gamma}_{1}}\right\},$$

$$\mathcal{A}_{34} = E\left\{\frac{\partial \hat{\mathbf{U}}_{i21}(\mathcal{D}_{i}; \boldsymbol{\gamma}_{1}, \boldsymbol{\phi}_{2})}{\partial \boldsymbol{\gamma}_{2}}\right\}, \mathcal{A}_{33} = E\left\{\frac{\partial \hat{\mathbf{U}}_{i21}(\mathcal{D}_{i}; \boldsymbol{\gamma}_{1}, \boldsymbol{\phi}_{2})}{\partial \boldsymbol{\alpha}_{1}}\right\},$$

$$\mathcal{A}_{35} = E\left\{\frac{\partial \hat{\mathbf{U}}_{i21}(\mathcal{D}_{i}; \boldsymbol{\gamma}_{1}, \boldsymbol{\phi}_{2})}{\partial \boldsymbol{\theta}_{1}}\right\}, \mathcal{A}_{36} = E\left\{\frac{\partial \hat{\mathbf{U}}_{i21}(\mathcal{D}_{i}; \boldsymbol{\gamma}_{1}, \boldsymbol{\phi}_{2})}{\partial \boldsymbol{\theta}_{2}}\right\},$$

$$\mathcal{A}_{44} = E\left\{\frac{\partial \mathbf{U}_{i22}(\mathcal{D}_{i}; \boldsymbol{\alpha}_{2})}{\partial \boldsymbol{\alpha}_{1}}\right\}, \mathcal{A}_{51} = E\left\{\frac{\partial \mathbf{U}_{i231}(\mathcal{D}_{i}; \boldsymbol{\gamma}_{1}, \boldsymbol{\theta}_{1})}{\partial \boldsymbol{\gamma}_{1}}\right\},$$

$$\mathcal{A}_{55} = E\left\{\frac{\partial \mathbf{U}_{i231}(\mathcal{D}_{i}; \boldsymbol{\gamma}_{1}, \boldsymbol{\theta}_{1})}{\partial \boldsymbol{\theta}_{1}}\right\}, \text{ and } \mathcal{A}_{66} = E\left\{\frac{\partial \mathbf{U}_{i232}(\mathcal{D}_{i}; \boldsymbol{\theta}_{0})}{\partial \boldsymbol{\theta}_{0}}\right\}$$

As $n \to \infty$.

$$\frac{1}{n} \sum_{i=1}^{n} \hat{\mathbf{U}}_{i}(\mathbf{\Omega}) \hat{\mathbf{U}}_{i}(\mathbf{\Omega})'$$

converges in probability to

$$E\left\{\hat{\mathbf{U}}_{i}(\mathbf{\Omega})\hat{\mathbf{U}}_{i}(\mathbf{\Omega})'\right\} = \mathcal{B}(\mathbf{\Omega})$$

Due to the consistency property of estimators for γ , we have

$$\sqrt{n}\left(\hat{\boldsymbol{\Omega}} - \boldsymbol{\Omega}\right) \stackrel{D}{\rightarrow} MVN\left\{\boldsymbol{0}, \boldsymbol{\Sigma}(\boldsymbol{\Omega})\right\}$$

where $\mathbf{\Sigma}(\mathbf{\Omega}) = \mathcal{A}^{-1}(\mathbf{\Omega})\mathcal{B}(\mathbf{\Omega})\left\{\mathcal{A}^{-1}(\mathbf{\Omega})\right\}'$ and

$$\mathcal{A}(\Omega) = egin{pmatrix} \mathcal{A}_{11} & \mathcal{A}_{12} & \mathbf{0} & \mathbf{0} & \mathbf{0} & \mathbf{0} \ \mathbf{0} & \mathcal{A}_{22} & \mathbf{0} & \mathbf{0} & \mathbf{0} & \mathbf{0} \ \mathcal{A}_{31} & \mathbf{0} & \mathcal{A}_{33} & \mathcal{A}_{34} & \mathcal{A}_{35} & \mathcal{A}_{36} \ \mathbf{0} & \mathbf{0} & \mathbf{0} & \mathcal{A}_{44} & \mathbf{0} & \mathbf{0} \ \mathcal{A}_{51} & \mathbf{0} & \mathbf{0} & \mathbf{0} & \mathcal{A}_{55} & \mathbf{0} \ \mathbf{0} & \mathbf{0} & \mathbf{0} & \mathbf{0} & \mathcal{A}_{66} \end{pmatrix}.$$

D Implementation of Multiple Imputation in Data Application

In the Detroit dataset, we observed missing values in the covariates for 159 out of 377 mothers. To address this, we employ multiple imputation by chained equations (MICE), a robust technique implemented through the mice package in R.(Van Buuren and Groothuis-Oudshoorn, 2011)

The MICE procedure operates under the missing at random (MAR) assumption, which states that the probability of data being missing depends only on the observed data, and not on the unobserved values themselves. Under this assumption, we generate 20 imputed datasets.

To be more specific, the imputation model included the three latent outcome variables: executive function (EF), mathematics achievement (Math), and learning and memory (LM). In the Detroit study, EF is assessed using seven tests, while both Math and LM are evaluated using six tests. Following Dang et al. Dang et al. (2023), first-order confirmatory factor analysis (CFA) is employed to integrate these multiple observed variables within each domain into a single latent variable for EF, Math, and LM, respectively. These three latent variables were treated as outcomes in our multivariate analysis. We also include the exposure variables, which are prenatal drinking status and average daily absolute alcohol consumption (AA/day) during pregnancy. Additionally, all variables included in the two propensity score models (as detailed in Table 6 of the main text) are incorporated. We also include two auxiliary variables: the proportion of drinking days and the amount of alcohol consumed per drinking occasion across pregnancy. The inclusion of auxiliary variables, which are correlated with either the outcome variables or the missingness mechanism, can improve the accuracy and efficiency of the imputations.(White et al., 2011)

Regarding the imputation methodology, logistic regression is employed for the binary variables (child's gender and mother's marital status), and predictive mean matching (PMM) addresses all other continuous variables. The default chained equations algorithm performs five iterations for each imputation.